[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 35948
1. Ikezoe T, Yang J, Nishioka C, Takezaki Y, Tasaka T, Togitani K, Koeffler HP, Yokoyama A: A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia; 2009 Sep;23(9):1564-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found in this study that PLK1 was aberrantly highly expressed in a variety of human leukemia cell lines (n=20), as well as, freshly isolated leukemia cells from individuals with acute myelogenous leukemia (n=50) and acute lymphoblastic leukemia (n=15) compared with bone marrow mononuclear cells from healthy volunteers (n=13) (acute myelogenous leukemia, P=0.016; acute lymphoblastic leukemia, P=0.008), as measured by real-time RT-PCR.
  • Downregulation of PLK1 by a small interfering RNA in NB4 acute myelogenous leukemia cells inhibited their proliferation.
  • The compound-induced growth inhibition, caused accumulation of cells in the G2/M phase of the cell cycle and mediated apoptosis of human leukemia cells.
  • Pre-treatment of cells with the caspase inhibitor Z-VAD-FMK attenuated the action of GW843682X in leukemia cells, indicating the involvement of the caspase pathway in the PLK1 inhibitor-mediated apoptosis.
  • Furthermore, we found that the PLK1 inhibitor synergistically potentiated the growth inhibition and apoptosis of leukemia cells when combined with tubulin-depolymerizing agent vincristine.
  • Taken together, targeting PLK1 may be a promising treatment strategy for individuals with leukemia.
  • [MeSH-major] Benzimidazoles / pharmacology. Cell Cycle Proteins / antagonists & inhibitors. Leukemia / drug therapy. Protein Kinase Inhibitors / pharmacology. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Proto-Oncogene Proteins / antagonists & inhibitors. Thiophenes / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Cell Division / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. G2 Phase / drug effects. Humans. Phosphorylation. RNA, Messenger / analysis. Vincristine / pharmacology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19421227.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-((2-(trifluoromethyl)benzyl)oxy)thiophene-2-carboxamide; 0 / Benzimidazoles; 0 / Cell Cycle Proteins; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Thiophenes; 5J49Q6B70F / Vincristine; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / polo-like kinase 1
  •  go-up   go-down


2. Hsieh AT, Anthony JC, Diersen-Schade DA, Rumsey SC, Lawrence P, Li C, Nathanielsz PW, Brenna JT: The influence of moderate and high dietary long chain polyunsaturated fatty acids (LCPUFA) on baboon neonate tissue fatty acids. Pediatr Res; 2007 May;61(5 Pt 1):537-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Docosahexaenoic acid (DHA) and arachidonic acid (ARA) are now common ingredients in commercial infant formulas, however, the optimal levels have not been established.
  • Our previous data showed that the current amount of DHA in U.S. term formulas, 0.3%w/w, is insufficient to normalize cerebral cortex DHA to levels in breastfed baboon neonate controls (Diau et al.: BMC Medicine 3: 11, 2005).
  • DHA increased significantly in liver, heart, and plasma (all C < L < L3), RBC (C < L, L3), and CNS regions: precentral gyrus (C < L < L3), frontal cortex, inferior and superior colliculi, globus pallidus, and caudate (all C < L, L3).

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Res. 2007 May;61(5 Pt 1):518-9 [17413853.001]
  • (PMID = 17413857.001).
  • [ISSN] 0031-3998
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / P01 HD021350; United States / NIDDK NIH HHS / DK / DK07158
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Fatty Acids; 0 / Fatty Acids, Unsaturated; 0 / Tissue Extracts; 25167-62-8 / Docosahexaenoic Acids; 27YG812J1I / Arachidonic Acid
  •  go-up   go-down


3. Vey N, Thomas X, Picard C, Kovascovicz T, Charin C, Cayuela JM, Dombret H, Dastugue N, Huguet F, Bastard C, Stamatoulas A, Giollant M, Tournilhac O, Macintyre E, Buzyn A, Bories D, Kuentz M, Dreyfus F, Delannoy A, Raynaud S, Gratecos N, Bordessoule D, de Botton S, Preudhomme C, Reman O, Troussard X, Pigneux A, Bilhou C, Vernant JP, Boucheix C, Gabert J, GET-LALA Group the Swiss Group for Clinical Cancer Research (SAKK): Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia; 2006 Dec;20(12):2155-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study.
  • Adult patients with acute lymphoblastic leukemia (ALL) and t(1;19)/E2A-PBX1 or t(4;11)/MLL-AF4 have a poor outcome.
  • CR rates achieved by MLL and E2A groups were similar to other B-cell ALL (87, 82 and 86% respectively).
  • The results of this study show that chemotherapy intensification did not overcome the poor prognosis of adults with t(1;19)/E2A-PBX1.
  • [MeSH-major] Burkitt Lymphoma / genetics. Burkitt Lymphoma / therapy. Hematopoietic Stem Cell Transplantation. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Basic Helix-Loop-Helix Transcription Factors / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 19 / genetics. Chromosomes, Human, Pair 4 / genetics. DNA-Binding Proteins / genetics. Female. Histone-Lysine N-Methyltransferase. Humans. Male. Middle Aged. Myeloid-Lymphoid Leukemia Protein / genetics. Nuclear Proteins / genetics. Prospective Studies. Proto-Oncogene Proteins / genetics. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17039234.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / TCF3 protein, human; 0 / pbx1 protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 150826-18-9 / AFF1 protein, human; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


Advertisement
4. Patel SR, Ortín M, Cohen BJ, Borrow R, Irving D, Sheldon J, Heath PT: Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis; 2007 Mar 1;44(5):635-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revaccination of children after completion of standard chemotherapy for acute leukemia.
  • BACKGROUND: After the treatment of patients with acute leukemia, there is a decrease in vaccine-specific antibody and an increased susceptibility to certain vaccine-preventable diseases.
  • All children received a single dose of Haemophilus influenzae type b (Hib), tetanus, diphtheria, acellular pertussis, meningococcus C, polio, measles, mumps, and rubella vaccines > or = 6 months after completion of treatment.
  • CONCLUSION: Revaccination of children after standard chemotherapy is important, and protection can be achieved in the majority of these children using a simple schedule of 1 vaccine dose at 6 months after completion of leukemia therapy.
  • [MeSH-major] Leukemia, Myeloid / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Vaccines / immunology
  • [MeSH-minor] Acute Disease. Adolescent. Bacterial Capsules. Child. Child, Preschool. Diphtheria Toxoid / administration & dosage. Diphtheria Toxoid / immunology. Haemophilus Vaccines / administration & dosage. Haemophilus Vaccines / immunology. Humans. Immunization Schedule. Immunosuppressive Agents / therapeutic use. Infant. Measles Vaccine / administration & dosage. Measles Vaccine / immunology. Meningococcal Vaccines / administration & dosage. Meningococcal Vaccines / immunology. Mumps Vaccine / administration & dosage. Mumps Vaccine / immunology. Poliovirus Vaccines / administration & dosage. Poliovirus Vaccines / immunology. Polysaccharides, Bacterial / administration & dosage. Polysaccharides, Bacterial / immunology. Rubella Vaccine / administration & dosage. Rubella Vaccine / immunology. Tetanus Toxoid / administration & dosage. Tetanus Toxoid / immunology. Vaccines, Acellular / administration & dosage. Vaccines, Acellular / immunology

  • MedlinePlus Health Information. consumer health - Immunization.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Infect Dis. 2007 Mar 1;44(5):643-5 [17278053.001]
  • (PMID = 17278052.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphtheria Toxoid; 0 / Haemophilus Vaccines; 0 / Haemophilus influenzae type b polysaccharide vaccine; 0 / Immunosuppressive Agents; 0 / Measles Vaccine; 0 / Meningococcal Vaccines; 0 / Mumps Vaccine; 0 / Poliovirus Vaccines; 0 / Polysaccharides, Bacterial; 0 / Rubella Vaccine; 0 / Tetanus Toxoid; 0 / Vaccines; 0 / Vaccines, Acellular
  •  go-up   go-down


5. Hernández-Espinosa D, Miñano A, Martínez C, Pérez-Ceballos E, Heras I, Fuster JL, Vicente V, Corral J: L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases. Am J Pathol; 2006 Jul;169(1):142-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases.
  • Interestingly, l-asparaginase treatment of acute lymphoblastic leukemia patients causes severe deficiency in the serpin antithrombin.
  • We studied the consequences of this drug on antithrombin levels, activity, conformation, and immunohistological and ultrastructural features in plasma from acute lymphoblastic leukemia patients, HepG2 cells, and plasma and livers from mice treated with this drug.
  • Additionally, we evaluated intracellular deposition of alpha1-antitrypsin. l-Asparaginase did not affect functional or conformational parameters of mature antithrombin; however, patients and mice displayed severe type I deficiency with no abnormal conformations of circulating antithrombin.
  • This is the first report of a conformational drug-associated effect on serpins without genetic factors involved. l-Asparaginase treatment induces severe, acquired, and transient type I deficiency of antithrombin (and alpha1-antitrypsin) with intracellular accumulation of the nascent molecule, increasing the risk of thrombosis.
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Line, Tumor. Electrophoresis, Polyacrylamide Gel. Factor Xa / drug effects. Factor Xa / metabolism. Humans. Liver / chemistry. Liver / metabolism. Male. Mice. Microscopy, Electron, Transmission. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Protein Conformation. alpha 1-Antitrypsin / drug effects. alpha 1-Antitrypsin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2005 Feb;90(2):238-46 [15710578.001]
  • [Cites] Cancer. 1982 Aug 1;50(3):451-6 [7046902.001]
  • [Cites] J Thromb Haemost. 2005 Sep;3(9):1985-92 [16102104.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3388-96 [10552948.001]
  • [Cites] Leuk Res. 2000 Jul;24(7):559-65 [10867129.001]
  • [Cites] J Clin Invest. 2000 Oct;106(7):873-8 [11018075.001]
  • [Cites] Genome Res. 2000 Dec;10(12):1845-64 [11116082.001]
  • [Cites] Thromb Haemost. 2001 Jul;86(1):14-22 [11487000.001]
  • [Cites] Exp Mol Pathol. 2001 Dec;71(3):241-6 [11733949.001]
  • [Cites] N Engl J Med. 2002 Jan 3;346(1):45-53 [11778003.001]
  • [Cites] Hepatology. 2002 May;35(5):1053-62 [11981755.001]
  • [Cites] Nat Rev Genet. 2002 Oct;3(10):759-68 [12360234.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2529-33 [12517808.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15116-22 [12578831.001]
  • [Cites] J Neurochem. 2003 Jun;85(5):1117-25 [12753071.001]
  • [Cites] Clin Chem. 2003 Oct;49(10):1710-1 [14500607.001]
  • [Cites] Biochem Soc Symp. 2003;(70):163-78 [14587291.001]
  • [Cites] J Lab Clin Med. 2003 Nov;142(5):298-305 [14647033.001]
  • [Cites] Electrophoresis. 2003 Dec;24(24):4282-90 [14679575.001]
  • [Cites] Thromb Res. 1983 Feb 15;29(4):437-42 [6857592.001]
  • [Cites] Blood. 1994 Jan 15;83(2):386-91 [8286739.001]
  • [Cites] Blood Coagul Fibrinolysis. 1994 Jan;5 Suppl 1:S24-36; discussion S59-64 [8186353.001]
  • [Cites] J Clin Invest. 1994 Dec;94(6):2265-74 [7989582.001]
  • [Cites] Int J Clin Lab Res. 1995;25(3):146-8 [8562977.001]
  • [Cites] Biochem J. 1997 May 15;324 ( Pt 1):1-18 [9164834.001]
  • [Cites] Lancet. 1997 Jul 12;350(9071):134-8 [9228977.001]
  • [Cites] Mutat Res. 2005 Jan 6;569(1-2):29-63 [15603751.001]
  • [Cites] J Thromb Haemost. 2004 Dec;2(12):2170-7 [15613023.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):895-9 [14685250.001]
  • [Cites] Thromb Res. 2003;111(6):321-7 [14698648.001]
  • [Cites] Curr Med Chem. 2004 Feb;11(4):491-9 [14965229.001]
  • [Cites] J Gastroenterol. 2004;39(4):391-6 [15168253.001]
  • [Cites] J Bioenerg Biomembr. 2004 Aug;36(4):303-7 [15377862.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1973;39:185-248 [4583638.001]
  • [Cites] Lancet. 1980 Mar 22;1(8169):649-50 [6102647.001]
  • [Cites] Med Pediatr Oncol. 1979;7(4):335-40 [296786.001]
  • [Cites] Curr Protein Pept Sci. 2005 Apr;6(2):197-203 [15853655.001]
  • (PMID = 16816368.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha 1-Antitrypsin; 9001-31-4 / Fibrin; EC 3.4.21.6 / Factor Xa; EC 3.5.1.1 / Asparaginase
  • [Other-IDs] NLM/ PMC1698772
  •  go-up   go-down


6. Wilcken B: Improving child health--newborn screening for all? Ann Acad Med Singapore; 2008 Dec;37(12 Suppl):3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over the last 40 years newborn screening has been an undoubted success and many thousands of children have been saved from mental retardation and other problems because of early diagnosis of their disorders.


7. Schrappe M: Mitoxantrone in first-relapse paediatric ALL: the ALL R3 trial. Lancet; 2010 Dec 11;376(9757):1968-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Mitoxantrone / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lancet. 2010 Dec 11;376(9757):2009-17 [21131038.001]
  • (PMID = 21131040.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; BZ114NVM5P / Mitoxantrone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


8. Seely EW, Williams GH: Education for physician clinical researchers: should one size fit all? Clin Transl Sci; 2010 Feb;3(1):8-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Education for physician clinical researchers: should one size fit all?
  • [MeSH-major] Education, Graduate / organization & administration. Education, Medical, Graduate / organization & administration. Translational Medical Research / education. Translational Medical Research / manpower
  • [MeSH-minor] Career Choice. Health Manpower. Humans. Medicine / statistics & numerical data. Program Development. Specialization. Students, Medical. United States

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS Med. 2006 Sep;3(9):e378 [16953661.001]
  • [Cites] JAMA. 2007 Jun 13;297(22):2496-501 [17565084.001]
  • [Cites] Acad Med. 2009 Apr;84(4):433-8 [19318772.001]
  • [Cites] Acad Med. 2009 Apr;84(4):439-45 [19318774.001]
  • [Cites] JAMA. 1998 Oct 28;280(16):1427-31 [9801003.001]
  • (PMID = 20443945.001).
  • [ISSN] 1752-8062
  • [Journal-full-title] Clinical and translational science
  • [ISO-abbreviation] Clin Transl Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Malone B: The Global Nursing Community: it's a small world after all. AORN J; 2009 Jun;89(6):973-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Global Nursing Community: it's a small world after all.
  • [MeSH-major] Cooperative Behavior. Global Health. Interinstitutional Relations. International Council of Nurses / organization & administration. Operating Room Nursing / organization & administration. Societies, Nursing / organization & administration
  • [MeSH-minor] Curriculum. Education, Nursing, Baccalaureate. Humans. Personnel Selection

  • MedlinePlus Health Information. consumer health - International Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500697.001).
  • [ISSN] 0001-2092
  • [Journal-full-title] AORN journal
  • [ISO-abbreviation] AORN J
  • [Language] eng
  • [Publication-type] Congresses; Editorial
  • [Publication-country] United States
  •  go-up   go-down


10. Kelly K, Swords R, Kilcoyne A, Sankhala K, Mahalingam D, Padmanabhan S, Giles F: Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow. Leuk Lymphoma; 2009 Feb;50(2):297-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow.
  • [MeSH-major] Elbow / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19160124.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


11. Spiegler BJ, Kennedy K, Maze R, Greenberg ML, Weitzman S, Hitzler JK, Nathan PC: Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J Clin Oncol; 2006 Aug 20;24(24):3858-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.
  • PURPOSE: Cranial radiation therapy (CRT) is associated with neurocognitive morbidity in survivors of childhood acute lymphoblastic leukemia (ALL).
  • The impact of chemotherapy-only protocols on neurocognitive outcomes is unclear, and the importance of systemic MTX dose has not been established.
  • RESULTS: Neurocognitive assessment was conducted at least 5 years after diagnosis (mean, 10.5 years, standard deviation, 2.7 years).
  • In this cohort, the dose of IV MTX did not influence these outcomes.
  • [MeSH-major] Cognition / drug effects. Cognition / radiation effects. Cranial Irradiation / adverse effects. Methotrexate / administration & dosage. Methotrexate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Feb 20;25(6):734-5; author reply 735 [17308283.001]
  • [ErratumIn] J Clin Oncol. 2006 Nov 10;24(32):5181
  • (PMID = 16921038.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


12. Lee KJ: Healthcare: affordable quality coverage for all. Otolaryngol Head Neck Surg; 2009 Jun;140(6):775-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The amount spent on healthcare in the United States is sufficient to meet everyone's needs; the reason it does not is that the money is misspent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467390.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Shults EE, Velder J, Schmalz HG, Chernov SV, Rubalova TV, Gatilov YV, Henze G, Tolstikov GA, Prokop A: Gram-scale synthesis of pinusolide and evaluation of its antileukemic potential. Bioorg Med Chem Lett; 2006 Aug 15;16(16):4228-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pinusolide (1), a known platelet-activating factor (PAF) receptor binding antagonist, was synthesized from lambertianic acid (2), a labdane-type diterpene readily accessible in multigram quantities from the Siberian pine tree.
  • It was shown that 1 not only decreases the proliferation activity of tumor cells at relatively low concentrations but specifically induces apoptosis at 100 microM via the mitochondrial pathway in the Burkitt lymphoma cell line BJAB.
  • Also, using primary lymphoblasts and leukemic cells from children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), a significant DNA fragmentation in pinusolide-treated cells could be detected in an ex vivo apoptosis assay.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / pharmacology. Diterpenes / chemical synthesis. Diterpenes / pharmacology. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Carboxylic Acids / chemistry. Cell Line. Cell Line, Tumor. Crystallography, X-Ray. DNA Fragmentation. Dose-Response Relationship, Drug. Drug Design. Humans. Mitochondria / metabolism. Models, Chemical. Models, Molecular. Naphthalenes / chemistry

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16781150.001).
  • [ISSN] 0960-894X
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carboxylic Acids; 0 / Diterpenes; 0 / Naphthalenes; 31685-80-0 / pinusolide; 4966-13-6 / lambertianic acid
  •  go-up   go-down


14. Yang L, Luo Y, Wei J: Integrative genomic analyses on Ikaros and its expression related to solid cancer prognosis. Oncol Rep; 2010 Aug;24(2):571-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, except rat and Xenopus tropicalis Ikaros proteins, which lack the first C2H2-type 1 Zinc finger region, all identified Ikaros proteins contain six C2H2-type 1 Zinc finger regions.
  • Besides the reported acute lymphoblastic leukemia (ALL), the expression of Ikaros was related to the prognosis of 13 cases of cancers including blood cancers, breast, lung, ovarian and skin cancer.
  • [MeSH-major] Genomics / methods. Ikaros Transcription Factor / genetics. Neoplasms / diagnosis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596648.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / IKZF1 protein, human; 148971-36-2 / Ikaros Transcription Factor
  •  go-up   go-down


15. Sun XF, Han B, Feng J, Zhou DB, Wang SJ, Xu Y, Chen JL, Jiao L, Zhang W, Li J, Duan MH, Zhu TN, Zou N, Hua BL, Cai HC, Zhao YQ: [Clinical features of invasive pulmonary fungal infection secondary to malignant blood diseases]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct;31(5):575-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The incidences of IPFI secondary to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), and aplastic anemia (AA) were 4.6%, 3.2%, 2.8%, and 2.5%, respectively.
  • [MeSH-major] Hematologic Neoplasms / complications. Lung Diseases, Fungal / diagnosis. Lung Diseases, Fungal / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19968074.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Chen X, Zheng Y, Zheng W, Gu K, Chen Z, Lu W, Shu XO: The effect of regular exercise on quality of life among breast cancer survivors. Am J Epidemiol; 2009 Oct 1;170(7):854-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors evaluated the effect of regular exercise during the first 36 months after cancer diagnosis on quality of life (QOL) in a population-based cohort study of 1,829 Chinese women diagnosed with breast cancer.
  • The women were identified between 2002 and 2004 and were invited to participate in the study about 6 months after cancer diagnosis.
  • Exercise was assessed approximately 6, 18, and 36 months after diagnosis, and a metabolic equivalent task (MET) score in hours per week was derived.
  • The exercise-QOL association remained stable over time after cancer diagnosis.
  • This study suggests that regular exercise after breast cancer diagnosis improves QOL.


17. Pais I, Hallschmid M, Jauch-Chara K, Schmid SM, Oltmanns KM, Peters A, Born J, Schultes B: Mood and cognitive functions during acute euglycaemia and mild hyperglycaemia in type 2 diabetic patients. Exp Clin Endocrinol Diabetes; 2007 Jan;115(1):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mood and cognitive functions during acute euglycaemia and mild hyperglycaemia in type 2 diabetic patients.
  • INTRODUCTION: Hyperglycaemia at levels above 15 mmol/l has been shown to impair cognitive functions in type 2 diabetic patients, while effects of mild hyperglycaemia and acute euglycaemia on mood and cognition have rarely been compared.
  • We examined mood and cognitive functions in patients with T2DM during acute euglycaemia in comparison with moderate hyperglycaemia.
  • Self-estimated blood glucose levels were higher during the hyper- than euglycaemic condition (8.6 +/- 2.5 vs 7.2 +/- 1.2 mmol/l; p<0.05) although most individual estimations did not match the actual glucose levels.
  • Counterregulatory hormone levels did not differ (all p>0.25).
  • CONCLUSIONS: Data indicate that T2DM patients are not cognitively impaired by moderate hyperglycaemia (10.5 mmol/l), pointing to the possibility of a glycaemic threshold for cognitive impairments at higher glycaemic levels.
  • [MeSH-major] Affect. Cognition. Diabetes Mellitus, Type 2 / physiopathology. Hyperglycemia / physiopathology

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17286234.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


18. Crews KR, Zhou Y, Pauley JL, Howard SC, Jeha S, Relling MV, Pui CH: Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia. Cancer; 2010 Jan 1;116(1):227-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia.
  • BACKGROUND: Allopurinol and urate oxidase are both effective in preventing or treating hyperuricemia during remission induction therapy for lymphoid malignancies, but to the authors' knowledge, their effects on concomitant anticancer drug therapy have not been compared.
  • METHODS: The authors compared plasma methotrexate pharmacokinetics in pediatric patients with newly diagnosed acute lymphoblastic leukemia who received concomitant allopurinol (n = 20) versus those treated with nonrecombinant or recombinant urate oxidase (n = 96) during high-dose methotrexate administration before conventional remission induction therapy.
  • Hence, during remission induction therapy for lymphoid malignancies, the authors concluded that renally excreted drugs should be monitored closely, especially in patients who are receiving allopurinol.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827857497 for PMID:19834958 [PharmGKB] .
  • Hazardous Substances Data Bank. Allopurinol .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Cancer Society.
  • [Cites] Pediatrics. 1988 Dec;82(6):863-9 [3186376.001]
  • [Cites] J Pediatr. 1986 Aug;109(2):292-8 [3461147.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1667-72 [8040679.001]
  • [Cites] J Clin Invest. 1994 Nov;94(5):1996-2001 [7525652.001]
  • [Cites] Leukemia. 1996 Jan;10(1):56-60 [8558939.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1252-61 [8648381.001]
  • [Cites] Leukemia. 1997 Nov;11(11):1813-6 [9369411.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2281-5 [9649146.001]
  • [Cites] Blood. 1998 Jul 15;92(2):411-5 [9657739.001]
  • [Cites] Semin Oncol Nurs. 1998 Nov;14(4):312-20 [9839344.001]
  • [Cites] JAMA. 1965 Jul 5;193:1-6 [14297704.001]
  • [Cites] Leukemia. 2005 Jan;19(1):34-8 [15510203.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2767-78 [18509186.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] Leukemia. 2000 Feb;14(2):221-5 [10673736.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):697-704 [11157020.001]
  • [Cites] Blood. 2001 May 15;97(10):2998-3003 [11342423.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1505-9 [11587206.001]
  • [Cites] Semin Hematol. 2001 Oct;38(4 Suppl 10):4-8 [11694945.001]
  • [Cites] Expert Opin Pharmacother. 2002 Apr;3(4):433-42 [11934348.001]
  • [Cites] Ann Oncol. 2002 May;13(5):789-95 [12075750.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4402-6 [14581437.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] N Engl J Med. 1966 Mar 3;274(9):481-6 [5904287.001]
  • [Cites] N Engl J Med. 1969 Feb 20;280(8):426-7 [5763090.001]
  • [Cites] Semin Oncol. 1989 Dec;16(6):504-15 [2688110.001]
  • (PMID = 19834958.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA023099-299002; None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / CA23099; None / None / / R01 CA051001-15; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / U10 CA031566-21; United States / NCI NIH HHS / CA / P01 CA023099; United States / NCI NIH HHS / CA / U10 CA031566; United States / NCI NIH HHS / CA / R01 CA051001-15; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / CA31566; United States / NCI NIH HHS / CA / P30 CA021765-31; United States / NCI NIH HHS / CA / CA023099-299002; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / CA51001; United States / NCI NIH HHS / CA / CA32053; United States / NCI NIH HHS / CA / CA031566-21
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 268B43MJ25 / Uric Acid; 63CZ7GJN5I / Allopurinol; EC 1.7.3.3 / Urate Oxidase; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS149924; NLM/ PMC2846832
  •  go-up   go-down


19. Koppen IJ, Hermans FJ, Kaspers GJ: Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia. Br J Haematol; 2010 Jan;148(1):3-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia.
  • Acute lymphoblastic leukaemia (ALL) is the most common paediatric cancer, accounting for nearly 30% of all paediatric cancers and 80% of childhood leukaemias.
  • This includes an influence of the type of population studied, because there was a difference between Asian and European study results.
  • [MeSH-major] Folic Acid / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Child. Genes, Neoplasm / physiology. Genetic Predisposition to Disease. Humans. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827858523 for PMID:19775302 [PharmGKB] .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2010 Jun;149(5):797-8; author reply 799-800 [20148884.001]
  • (PMID = 19775302.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  • [Number-of-references] 43
  •  go-up   go-down


20. Reinfjell T, Lofstad GE, Nordahl HM, Vikan A, Diseth TH: Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioning. Eur J Cancer Care (Engl); 2009 Jul;18(4):364-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioning.
  • Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioningThe objective of this study is to assess the mental health and psychosocial adjustment of children in remission from acute lymphoblastic leukaemia (ALL), and parental functioning compared to healthy controls.
  • [MeSH-major] Adaptation, Psychological. Mental Disorders / epidemiology. Parents / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology

  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473372.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Shin IH, Kang SY, Hong S, Kim SK, Seong GJ, Tak MK, Kim CY: Comparison of OCT and HRT findings among normal, normal tension glaucoma, and high tension glaucoma. Korean J Ophthalmol; 2008 Dec;22(4):236-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four quadrant RNFL thickness measurements were not significantly different between NTG and HTG (all p > 0.05).
  • [MeSH-major] Axons / pathology. Diagnostic Techniques, Ophthalmological. Glaucoma, Open-Angle / diagnosis. Optic Disk / pathology. Optic Nerve Diseases / diagnosis. Retinal Ganglion Cells / pathology. Tomography, Optical Coherence
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Ocular Hypertension / diagnosis. Retrospective Studies. Visual Field Tests. Visual Fields

  • Genetic Alliance. consumer health - Glaucoma.
  • MedlinePlus Health Information. consumer health - Optic Nerve Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 1967 Jul;78(1):35-43 [6067496.001]
  • [Cites] Korean J Ophthalmol. 1997 Dec;11(2):79-83 [9510648.001]
  • [Cites] Arch Ophthalmol. 1977 Dec;95(12):2149-56 [588106.001]
  • [Cites] Arch Ophthalmol. 1980 Sep;98(9):1564-71 [7425916.001]
  • [Cites] Arch Ophthalmol. 1982 Jan;100(1):135-46 [7055464.001]
  • [Cites] Arch Ophthalmol. 1982 May;100(5):807-14 [7082210.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1983;220(4):193-6 [6884783.001]
  • [Cites] Am J Ophthalmol. 1984 Jun;97(6):730-7 [6731537.001]
  • [Cites] Arch Ophthalmol. 1984 Dec;102(12):1766-71 [6508617.001]
  • [Cites] Am J Ophthalmol. 1989 May 15;107(5):453-64 [2712129.001]
  • [Cites] Int Ophthalmol. 1989 Jan;13(1-2):25-9 [2744951.001]
  • [Cites] Am J Ophthalmol. 1989 Oct 15;108(4):404-13 [2679110.001]
  • [Cites] Arch Ophthalmol. 1990 May;108(5):705-8 [2334330.001]
  • [Cites] Acta Ophthalmol (Copenh). 1990 Aug;68(4):445-9 [2220362.001]
  • [Cites] Arch Ophthalmol. 1991 Jan;109(1):77-83 [1987954.001]
  • [Cites] Am J Ophthalmol. 1991 Apr 15;111(4):485-90 [2012151.001]
  • [Cites] Arch Ophthalmol. 1991 Oct;109(10):1441-3 [1929937.001]
  • [Cites] Ophthalmology. 1992 Jan;99(1):19-28 [1741133.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1992 May;33(6):2012-8 [1582806.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1992;230(5):446-50 [1521811.001]
  • [Cites] Ophthalmology. 1993 May;100(5):587-97; discussion 597-8 [8493001.001]
  • [Cites] Arch Ophthalmol. 1994 Aug;112(8):1068-76 [8053821.001]
  • [Cites] Arch Ophthalmol. 1995 May;113(5):586-96 [7748128.001]
  • [Cites] Ophthalmology. 1996 Dec;103(12):2114-9 [9003346.001]
  • [Cites] Br J Ophthalmol. 1997 May;81(5):350-4 [9227197.001]
  • [Cites] Am J Ophthalmol. 1997 Dec;124(6):805-13 [9402827.001]
  • [Cites] J Glaucoma. 1997 Dec;6(6):370-6 [9407365.001]
  • [Cites] Trans Am Ophthalmol Soc. 1976;74:532-72 [867638.001]
  • (PMID = 19096240.001).
  • [ISSN] 1011-8942
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2629909
  •  go-up   go-down


22. Martin MB, Li CS, Rowland CC, Howard SC, Kaste SC: Correlation of bone age, dental age, and chronological age in survivors of childhood acute lymphoblastic leukaemia. Int J Paediatr Dent; 2008 May;18(3):217-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of bone age, dental age, and chronological age in survivors of childhood acute lymphoblastic leukaemia.
  • BACKGROUND: There is little information about oncotherapy-related dental development in childhood acute lymphoblastic leukaemia (ALL).
  • OBJECTIVE: The objective of this study was to compare bone age (BA) and dental age (DA) to chronological age (CA) in childhood ALL survivors.
  • We recorded patient demographics, therapeutic protocol, CA, DA, and BA.
  • The cohort was divided into three categories based on age at diagnosis (< 6 years, 6-9 years, > 9 years).
  • Median CA at diagnosis was 4.5 years (range: 0.1-11.0 years); time to study was 4.1 years (range: 0.3-11.4 years).
  • Abnormal BA, abnormal DA, and discrepancy between BA and DA are not statistically significantly associated with investigated patient or treatment factors.
  • [MeSH-major] Age Determination by Skeleton. Age Determination by Teeth. Child Development. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Survivors / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Child Development.
  • MedlinePlus Health Information. consumer health - Infant and Newborn Development.
  • MedlinePlus Health Information. consumer health - Toddler Development.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298546.001).
  • [ISSN] 1365-263X
  • [Journal-full-title] International journal of paediatric dentistry
  • [ISO-abbreviation] Int J Paediatr Dent
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P01 CA-20180; United States / NCI NIH HHS / CA / P30 CA-21765
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Kirimlioglu V, Sozen H, Turkoglu S, Haberal M: Protective effect of resveratrol, a red wine constituent polyphenol, on rats subjected to portal vein thrombosis. Transplant Proc; 2008 Jan-Feb;40(1):290-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One may advise patients undergoing liver transplantation and carrying certain cardiovascular disease risk factors to ingest foods containing R to minimize PVT.

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • Hazardous Substances Data Bank. RESVERATROL .
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261608.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Stilbenes; 4Y8F71G49Q / Malondialdehyde; E0399OZS9N / Cyclic AMP; GAN16C9B8O / Glutathione; Q369O8926L / resveratrol
  •  go-up   go-down


24. Russell JA, Savoie ML, Balogh A, Turner AR, Larratt L, Chaudhry MA, Storek J, Bahlis NJ, Brown CB, Quinlan D, Geddes M, Stewart DA: Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant; 2007 Jul;13(7):814-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.
  • A myeloablative conditioning regimen incorporating daily intravenous busulfan, fludarabine, and 400 cGy total-body irradiation was given before allogeneic stem cell transplantation (SCT) to 64 adults with acute leukemia in first and second remission.
  • Graft-versus-host disease (GVHD) prophylaxis included methotrexate, cyclosporine A, and rabbit antithymocyte globulin (Thymoglobulin).
  • For 31 matched related (MRD) and 33 alternate donor (AD) SCT the incidence of acute GVHD grade II-IV was 11% +/- 6% versus 35% +/- 9% (P = .047), acute GVHD grade III-IV was 0% versus 10% +/- 6% (P = .09), and chronic GVHD was 40% +/- 9% versus 66% +/- 9% (P = NS), respectively.
  • Projected disease-free (DFS) and overall survival (OS) at 3 years for acute myelogenous leukemia (AML) (n = 36) are the same at 83% +/- 6%, and for acute lymphoblastic leukemia (ALL) (n = 28) are 65% +/- 10% and 78% +/- 8%, respectively.
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / administration & dosage. Antilymphocyte Serum. Antineoplastic Agents / administration & dosage. Busulfan / administration & dosage. Cyclosporine / administration & dosage. Disease-Free Survival. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Humans. Immunosuppressive Agents / administration & dosage. Infusions, Intravenous. Male. Methotrexate / administration & dosage. Middle Aged. Myeloablative Agonists / administration & dosage. Remission Induction. Retrospective Studies. Survival Rate. Transplantation, Homologous. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580259.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antilymphocyte Serum; 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 0 / Myeloablative Agonists; 0 / thymoglobulin; 83HN0GTJ6D / Cyclosporine; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


25. Pannell RS, Fleming DM, Cross KW: The incidence of molluscum contagiosum, scabies and lichen planus. Epidemiol Infect; 2005 Dec;133(6):985-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of molluscum contagiosum, scabies and lichen planus.
  • We aimed to describe the incidence of new episodes of molluscum contagiosum, scabies and lichen planus presenting to general practitioners in England and Wales.
  • We examined data collected in a sentinel practice network (the Weekly Returns Service of the Royal College of General Practitioners) in which about half a million persons were observed each year over the period 1994-2003.
  • The incidence of molluscum contagiosum in males was 243/100,000 person-years and in females 231; of scabies, males 351, females 437; of lichen planus, males 32, females 37.
  • Incidence varied by year and age.
  • Ninety per cent of molluscum contagiosum episodes were reported in children aged 0-14 years, where incidence in 2000 (midpoint of a 6-year period of stable incidence) was 1265/100,000 (95% CI 1240-1290).
  • Scabies affected all ages and annual incidence ranged between 233 (95% CI 220-246) in 2003 and 470 (95% CI 452-488) in 2000.
  • Lichen planus occurred chiefly in persons aged over 45 years: incidence (all ages) ranged between 27 (95% CI 23-31) in 2003 and 43 (95% CI 37-49) in 1998.
  • The relative risk of female to male incidence (all ages) of molluscum contagiosum was 0.95 (95% CI 0.91-0.99); of scabies 1.25 (95% CI 1.21-1.28); and of lichen planus 1.19 (95% CI 1.08-1.13).
  • [MeSH-major] Family Practice / organization & administration. Lichen Planus / epidemiology. Molluscum Contagiosum / epidemiology. Scabies / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Incidence. Infant. Male. Middle Aged. Population Surveillance

  • MedlinePlus Health Information. consumer health - Scabies.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274495.001).
  • [ISSN] 0950-2688
  • [Journal-full-title] Epidemiology and infection
  • [ISO-abbreviation] Epidemiol. Infect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2870332
  •  go-up   go-down


26. Wang L, Lin D, Zhang X, Chen S, Wang M, Wang J: Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients. Leuk Res; 2005 Dec;29(12):1393-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients.
  • Genomic aberrations of Fms-like tyrosine kinase 3 (FLT3), including internal tandem duplication (ITD) and point mutations, have been demonstrated in 25-30% of adults acute myeloid leukemia (AML) and are markers of poor prognosis.
  • FLT3/ITD and D835 mutations were analyzed in 194 Chinese patients with acute leukemia and myelodysplastic syndromes (MDS) by polymerase chain reaction (PCR).
  • However, neither aberrations was found in 25 patients with acute lymphoblastic leukemia (ALL), 2 acute hybrid leukemia, 17 MDS and 7 chronic myeloid leukemia in blast crisis (CML-BC).
  • In contrast, D835 mutation was not associated with leukocytosis or low CR rate.
  • FLT3/ITD(+) patients treated with standard induction regimen could achieve lower complete remission rates compared with patients not harboring this defect.
  • [MeSH-major] Leukemia / genetics. Mutation, Missense. Tandem Repeat Sequences. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Amino Acid Sequence. Asian Continental Ancestry Group / genetics. DNA Mutational Analysis. Female. Humans. Leukocytosis. Male. Middle Aged. Molecular Sequence Data. Myelodysplastic Syndromes / genetics. Prognosis. Remission Induction


27. Chan KS, Keeler E, Schonlau M, Rosen M, Mangione-Smith R: How do ethnicity and primary language spoken at home affect management practices and outcomes in children and adolescents with asthma? Arch Pediatr Adolesc Med; 2005 Mar;159(3):283-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although Latino children and adolescents from English-speaking homes did worse than their non-Latino white peers, the decrements were modest and not statistically significant (P>.16 for all).

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15753274.001).
  • [ISSN] 1072-4710
  • [Journal-full-title] Archives of pediatrics & adolescent medicine
  • [ISO-abbreviation] Arch Pediatr Adolesc Med
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Mayo CS, Urie MM, Fitzgerald TJ: Hybrid IMRT plans--concurrently treating conventional and IMRT beams for improved breast irradiation and reduced planning time. Int J Radiat Oncol Biol Phys; 2005 Mar 1;61(3):922-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid IMRT plans--concurrently treating conventional and IMRT beams for improved breast irradiation and reduced planning time.
  • PURPOSE: To evaluate a hybrid intensity modulated radiation therapy (IMRT) technique as a class solution for treatment of the intact breast.
  • METHODS AND MATERIALS: The following five plan techniques were compared for 10 breast patients using dose-volume histogram analysis: conventional wedged-field tangents (Tangents), forward-planned field-within-a-field tangents (FIF), IMRT-only tangents (IMRT tangents), conventional open plus IMRT tangents (4-field hybrid), and conventional open plus IMRT tangents with 2 anterior oblique IMRT beams (6-field hybrid).
  • RESULTS: The 4-field hybrid and FIF achieved dose distributions better than Tangents and IMRT tangents.
  • The volume of tissue outside the planning target volume receiving > or =110% of prescribed dose was largest for IMRT tangents (average 158 cc) and least for 6-field hybrid (average 1 cc); the FIF and 4-field hybrid were comparable (average 15 cc).
  • Heart volume > or =30 Gy averaged 13 cc for all techniques, except Tangents, for which it was 32 cc.
  • Average total lung volume > or =20 Gy was 7% for all.
  • Contralateral breast doses were < 3% for all.
  • Planning time for hybrid techniques was significantly less than for conventional FIF technique.
  • CONCLUSIONS: The 4-field hybrid technique is a viable class solution.
  • The 6-field hybrid technique creates the most conformal dose distribution at the expense of more normal tissue receiving low dose.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Female. Humans. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708276.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Zhao X, Tang KJ, Tian Z, Chen LP, Mi YC, Wang JX: [FLT3 mutation in patients with acute lymphoblastic leukemia and its clinical significance]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct;31(5):522-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [FLT3 mutation in patients with acute lymphoblastic leukemia and its clinical significance].
  • OBJECTIVE: To investigate fms-like tyrosine kinase 3 (FLT3) mutation in patients with acute lymphoblastic leukemia (ALL) and its clinical significance.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19968062.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


30. Anoop P, Hargrave D, Zacharoulis S, Saran F: Diagnostic and therapeutic challenges owing to concurrent pontine glioma and acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2008 Jun;30(6):454-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and therapeutic challenges owing to concurrent pontine glioma and acute lymphoblastic leukemia.
  • The concurrent presence of a low-grade brain stem glioma and acute lymphoblastic leukemia in a genetically normal girl is presented.
  • The problems encountered with diagnosis and treatment are discussed here.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Glioma / pathology. Neoplasms, Multiple Primary / pathology. Pons / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525463.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Simoncig-Netjasov A, Vujović S, Ivović M, Tancić-Gajić M, Drezgić M: [Gaining weight and components of metabolic syndrome in the period of menopause]. Srp Arh Celok Lek; 2008 Sep-Oct;136(9-10):505-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gaining weight and components of metabolic syndrome in the period of menopause].
  • INTRODUCTION: Menopause induces redistribution of fat mass and development of abdominal obesity, increasing risk for metabolic syndrome (MS) by 60%.
  • Related cardiovascular diseases become a leading cause of morbidity and mortality in women after fifty years of age.
  • OBJECTIVE: The aim of this study was to investigate the influence of gaining weight on components of MS in the menopause.
  • METHOD: The study included 50 obese women, BMI=31.92 +/- 5.83 kg/m2, age 54.40 +/- 3.64, time since menopause 5.90 +/- 5.46 years, and 37 normal weight women, BMI = 23.50 +/- 2.13 kg/m2, age 53.92 +/- 3.95, time since menopause 5.96 +/- 4.92 years.
  • Both groups were divided according to the presence of MS into two subgroups.
  • Anthropometric characteristics and blood pressure were measured.
  • Blood was taken at 8 am for the following: fasting glucose, triglycerides, cholesterol, HDL, LDL, apolipoprotein A (ApoA), apolipoprotein B (ApoB), lipoprotein(a) (Lp(a)), C-reactive protein (CRP), fibrinogen, FSH, LH, prolactin, oestrogen, progesterone, testosterone and sex hormone-binding globulin (SHBG).
  • RESULTS: 66% of obese women had MS compared with 22% normal weight women.
  • Significant differences between groups were found for the following: weight, BMI, waist, hip circumference, waist/hip ratio, diastolic blood pressure, Lp(a), FSH, LH, prolactin (all p < 0.01) and fasting glucose (p < 0.05).
  • Obese women with and without MS were significantly diverse for the following: waist/hip ratio, systolic blood pressure and fasting glucose (all p < 0.01); age, BMI, waist circumference, triglycerides, HDL, Lp(a) and SHBG (all p < 0.05).
  • Normal weight women with and without MS had significantly different values of waist/hip ratio, systolic, diastolic blood pressure, triglycerides (all p < 0.01); HDL and testosterone (p < 0.05).
  • Significant differences were found between obese and normal weight women with MS in anthropometric characteristics, ApoA, Lp(a), fibrinogen (all p < 0.01) and FSH (p < 0.05).
  • CONCLUSION: Abdominal obesity significantly increases incidence of MS as a cluster of cardiovascular risk factors in the menopause.
  • [MeSH-major] Menopause / physiology. Metabolic Syndrome X / etiology. Weight Gain
  • [MeSH-minor] Body Fat Distribution. Female. Humans. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Menopause.
  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069342.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


32. Jacobs SS, Stork LC, Bostrom BC, Hutchinson R, Holcenberg J, Reaman GH, Erdmann G, Franklin J, Neglia JP, Steinberg SM, Balis FM, Adamson PC, Children's Oncology Group, National Cancer Institute: Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942). Pediatr Blood Cancer; 2007 Sep;49(3):250-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
  • BACKGROUND: Although mercaptopurine (MP) is conventionally used to treat childhood acute lymphoblastic leukemia (ALL), thioguanine (TG) is a more potent thiopurine in vitro and, when administered orally to patients, achieves cytotoxic drug concentrations in the cerebrospinal fluid (CSF).
  • Six patients (five males) experienced reversible veno-occlusive disease (VOD) while receiving oral TG, and the study was amended to discontinue TG, changing all patients to oral MP.
  • Red cell TG nucleotide concentrations during oral TG averaged 95 ng (570 pmol)/8x10(8) RBC, greater than concentrations reported with oral MP.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thioguanine / administration & dosage
  • [MeSH-minor] Administration, Oral. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Drug-Related Side Effects and Adverse Reactions. Female. Hepatic Veno-Occlusive Disease / chemically induced. Humans. Infant. Infusions, Intravenous. Male. Pilot Projects. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Oral cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THIOGUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16856155.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR00069; United States / NCI NIH HHS / CA / U10 CA 13539; United States / NCI NIH HHS / CA / U10 CA 98543
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; FTK8U1GZNX / Thioguanine
  •  go-up   go-down


33. Nishiwaki S, Terakura S, Yasuda T, Imahashi N, Sao H, Iida H, Kamiya Y, Niimi K, Morishita Y, Kohno A, Yokozawa T, Ohashi H, Sawa M, Kodera Y, Miyamura K: Outcome of allogeneic bone marrow transplantation from unrelated donors for adult Philadelphia chromosome-negative acute lymphocytic leukemia in first complete-remission. Int J Hematol; 2010 Apr;91(3):419-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of allogeneic bone marrow transplantation from unrelated donors for adult Philadelphia chromosome-negative acute lymphocytic leukemia in first complete-remission.
  • The indication of allogeneic stem cell transplantation (allo-SCT) for Philadelphia chromosome-negative acute lymphocytic leukemia [Ph(-) ALL] from unrelated donors is not established.
  • Leukemia-free survival (LFS) at 3 and 6 years from allo-SCT was 60.3 and 47.7%, respectively.
  • Our study suggested that unrelated allo-SCT could improve LFS of patients with a potential graft-versus-leukemia effect.
  • [MeSH-major] Bone Marrow Transplantation / immunology. Histocompatibility / immunology. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Graft vs Host Disease / immunology. Graft vs Host Disease / mortality. Humans. Incidence. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Tissue Donors. Transplantation, Homologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1307-25, ix [11147225.001]
  • [Cites] Bone Marrow Transplant. 2005 Jul;36(2):115-21 [15908969.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Bone Marrow Transplant. 1989 Jul;4(4):445-8 [2673466.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:162-92 [12446423.001]
  • [Cites] Br J Haematol. 1998 Mar;100(4):669-76 [9531332.001]
  • [Cites] Semin Oncol. 2000 Oct;27(5):540-59 [11049022.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(4):381-7 [17563735.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Haematologica. 1999 Oct;84(10):937-45 [10509043.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1408-16 [15486071.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Blood. 2008 Jul 15;112(2):426-34 [18398065.001]
  • [Cites] Int J Hematol. 1998 Dec;68(4):421-9 [9885441.001]
  • [Cites] Chest. 2005 Jul;128(1):153-61 [16002929.001]
  • [Cites] Haematologica. 2004 Feb;89(2):145-53 [15003889.001]
  • [Cites] Bone Marrow Transplant. 2001 Sep;28(5):425-34 [11593314.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(1):45-50 [16258531.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Apr;10(2):293-320 [8707757.001]
  • [Cites] N Engl J Med. 1999 Jul 1;341(1):14-21 [10387937.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Int J Hematol. 1998 Oct;68(3):279-89 [9846012.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] Respiration. 2004 Jul-Aug;71(4):301-26 [15316202.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4200-6 [12010826.001]
  • [Cites] Blood. 1981 Feb;57(2):267-76 [7004534.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1375-82 [18988865.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2464-71 [12011123.001]
  • [Cites] Transplant Proc. 1989 Jun;21(3 Suppl 1):51-62 [2662536.001]
  • [Cites] Bone Marrow Transplant. 2006 Feb;37(3):289-96 [16400341.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]
  • [Cites] Int J Hematol. 2007 Feb;85(2):163-9 [17321996.001]
  • [Cites] Ann Intern Med. 1986 Feb;104(2):168-75 [3511812.001]
  • (PMID = 20146028.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


34. Wu SW, Wu LF, Wang Q, Zhang WY: [Risk factors of adverse pregnancy outcomes during expectant management of early onset severe pre-eclampsia]. Zhonghua Fu Chan Ke Za Zhi; 2010 Mar;45(3):165-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Risk factors of adverse pregnancy outcomes during expectant management of early onset severe pre-eclampsia].
  • OBJECTIVE: To identify the risk factors of adverse pregnancy outcomes in expectant management of pregnant women with early onset severe pre-eclampsia (EOSP).
  • No significant differences was found between the two groups in the maternal age, times of previous pregnancies, prevalence of concurrent complications, pre-pregnant body mass index (BMI), proportion of women who had regular antenatal checks (P > 0.05). (2) Pregnant outcomes: the average duration of expectant management in the control group were similar to the adverse outcomes group [(6.5 +/- 8.2) days vs. (6.8 +/- 10.0) days, P > 0.05].
  • The adverse outcome group showed lower platelet (PLT) level and higher red blood cell (RBC) count and hematocrit compared with those of the control (all P < 0.01). (5) Liver and renal function: the alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), blood urea nitrogen (BUN) in the adverse outcome group were significantly higher than those of the control group (all P < 0.05), but the plasma level of total protein (TP), albumin (Alb), uric acid (UA) and creatinine (Cr) were similar between the two groups (P > 0.05). (6) Risk factor analysis: RBC count (OR = 3.68, 95%CI: 1.90-7.13), PLT count (OR = 0.99, 95%CI: 0.98-1.00) and the gestations at delivery (OR = 0.87, 95%CI: 0.80-0.94) were the risk factors of adverse pregnancy outcomes during the expectant management of EOSP.
  • [MeSH-major] Gestational Age. Pre-Eclampsia / therapy. Pregnancy Complications / epidemiology. Pregnancy Outcome


35. Latham N, Mason G: Frustration and perseveration in stereotypic captive animals: is a taste of enrichment worse than none at all? Behav Brain Res; 2010 Jul 29;211(1):96-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frustration and perseveration in stereotypic captive animals: is a taste of enrichment worse than none at all?
  • Stereotypic behaviours are common in animals in impoverished housing, arising from two complementary processes:.
  • (1) thwarted attempts to perform motivated behaviours;.
  • (2) forebrain dysfunction impeding normal behavioural inhibition.
  • When enriched animals are moved to impoverished housing, they are sometimes protected against developing stereotypic behaviour, but in other cases become even more stereotypic than animals housed lifelong without enrichment.
  • Negative contrast-induced frustration must occur in both scenarios.
  • We hypothesise that sustained behavioural responses to this frustration are prevented in the former by normalised forebrain function, but exacerbated in the latter by forebrain dysfunction.
  • ICRCD-1 mice reared in enriched or standard cages were re-caged at 3 months to standard conditions.
  • Here, previously-enriched mice became far more stereotypic than mice reared from birth in such conditions.
  • To investigate the role of frustration, we assessed both corticosterone output and motivation (break-point) to regain enrichments.
  • We also assessed perseveration via extinction learning.
  • As predicted, previously-enriched mice were as perseverative as standard-raised mice, and frustration seemed to play a causal role in their exacerbated stereotypic behaviour.
  • Previously-enriched mice showed higher motivations to access enrichments, and only in this group did these correlate with corticosterone levels after re-caging; furthermore only in previously-enriched mice did corticosterone responses to re-caging predict stereotypic behaviour 30 days later (males only).
  • All results need replicating and further investigation.
  • However, they suggest for the first time that individual risk factors related to the HPA axis predict stereotypic behaviour following enrichment-removal, and that previously-enriched mice have lasting motivational differences from standard-raised mice, suggesting sustained behavioural effects related to the frustration of enrichment-loss.
  • [MeSH-major] Behavior, Animal. Environment. Frustration. Motivation. Stereotyped Behavior
  • [MeSH-minor] Adaptation, Psychological. Adrenal Cortex Hormones / urine. Animals. Exploratory Behavior. Female. Housing, Animal. Linear Models. Male. Mice. Mice, Inbred ICR. Motor Activity. Stress, Psychological / urine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20230861.001).
  • [ISSN] 1872-7549
  • [Journal-full-title] Behavioural brain research
  • [ISO-abbreviation] Behav. Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


36. Anderson K, Devitt J, Cunningham J, Preece C, Cass A: "All they said was my kidneys were dead": Indigenous Australian patients' understanding of their chronic kidney disease. Med J Aust; 2008 Nov 3;189(9):499-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "All they said was my kidneys were dead": Indigenous Australian patients' understanding of their chronic kidney disease.
  • OBJECTIVES: To explore the understanding of both Indigenous and non-Indigenous Australians with end-stage kidney disease (ESKD) about the cause of their disease, and how this understanding could affect patients' engagement with their treatment.
  • This study confirms the need to develop shared understandings about chronic kidney disease and to put in place the high-quality and appropriate educational resources that patients need.

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976191.001).
  • [ISSN] 0025-729X
  • [Journal-full-title] The Medical journal of Australia
  • [ISO-abbreviation] Med. J. Aust.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


37. Barnett MH, Henderson AP, Prineas JW: The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion. Mult Scler; 2006 Apr;12(2):121-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion.
  • This has led to the prevailing consensus that a T-cell dependent, macrophage-mediated, autoimmune attack on constituents in the normal myelin sheath underlies the disease.
  • The prephagocytic changes in evolving lesions examined shortly after the onset of an MS relapse raise the possibility that oligodendrocyte cell death and associated changes within the myelin sheath initiate local macrophage scavenger activity, with subsequent amplification of the inflammatory response.
  • [MeSH-minor] Acute Disease. Free Radical Scavengers. Humans. Myelin Sheath / pathology. Th1 Cells / pathology

  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16629415.001).
  • [ISSN] 1352-4585
  • [Journal-full-title] Multiple sclerosis (Houndmills, Basingstoke, England)
  • [ISO-abbreviation] Mult. Scler.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Free Radical Scavengers
  • [Number-of-references] 58
  •  go-up   go-down


38. Eiser C, Davies H, Jenney M, Glaser A: Mothers' attitudes to the randomized controlled trial (RCT): the case of acute lymphoblastic leukaemia (ALL) in children. Child Care Health Dev; 2005 Sep;31(5):517-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mothers' attitudes to the randomized controlled trial (RCT): the case of acute lymphoblastic leukaemia (ALL) in children.
  • [MeSH-major] Mothers / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Randomized Controlled Trials as Topic / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101646.001).
  • [ISSN] 0305-1862
  • [Journal-full-title] Child: care, health and development
  • [ISO-abbreviation] Child Care Health Dev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


39. Elewaut D: Linking Crohn's disease and ankylosing spondylitis: it's all about genes! PLoS Genet; 2010 Dec 02;6(12):e1001223
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linking Crohn's disease and ankylosing spondylitis: it's all about genes!
  • [MeSH-major] Crohn Disease / genetics. Spondylitis, Ankylosing / genetics


40. Lønning PE: Tailored targeted therapy for all: a realistic and worthwhile objective? Breast Cancer Res; 2009;11 Suppl 3:S7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / genetics. Genetic Predisposition to Disease / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Mol Med. 2004 Mar;10(3):113-8 [15102353.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1260-6 [7908410.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1361-70 [9747867.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1474-81 [10334533.001]
  • [Cites] Curr Opin Pharmacol. 2005 Aug;5(4):388-93 [15955736.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 May;95(1-5):41-8 [15967659.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7483-90 [16234514.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Jan;2(1):26-33 [16264853.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2428-36 [16682728.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2914-8 [17121939.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1293-306 [17317675.001]
  • [Cites] Drugs. 2007;67(14):2101-8; discussion 2109-10 [17883289.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1368-76 [18316557.001]
  • [Cites] Endocr Rev. 2008 Apr;29(2):217-33 [18216219.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):80-6 [18343102.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):267-77 [19261255.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1382-7 [19224856.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2302-10 [19318481.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2552-8 [19318484.001]
  • [Cites] BMC Cancer. 2009;9:86 [19298662.001]
  • [Cites] J Clin Oncol. 2009 Aug 20;27(24):3881-6 [19620488.001]
  • [Cites] Br J Cancer. 2009 Oct 20;101(8):1253-60 [19755984.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2639-48 [10561337.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1577-81 [11410493.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Clin Breast Cancer. 2001 Jan;1(4):297-308; discussion 309 [11899352.001]
  • [Cites] Endocr Relat Cancer. 2003 Mar;10(1):1-21 [12653668.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):814-9 [15510162.001]
  • (PMID = 20030882.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / BRCA2 Protein; 0 / Biomarkers, Tumor; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 0 / Receptors, Estrogen; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2797687
  •  go-up   go-down


41. Stone K: All about polyclinics: Community hospitals are polyclinics by another name. BMJ; 2008 May 24;336(7654):1145
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] All about polyclinics: Community hospitals are polyclinics by another name.
  • [MeSH-major] Hospitals, Community / organization & administration. Outpatient Clinics, Hospital / organization & administration. Primary Health Care / organization & administration
  • [MeSH-minor] Great Britain. State Medicine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2008 Apr 26;336(7650):916-8 [18436945.001]
  • [CommentOn] BMJ. 2008 Apr 26;336(7650):916-8 [18436945.001]
  • (PMID = 18497376.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2394598
  •  go-up   go-down


42. Riel-Romero RM, Baumann RJ, Smith CD: An unusual complication of cancer treatment for acute lymphoblastic leukemia. J Neurooncol; 2005 Jul;73(3):269-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual complication of cancer treatment for acute lymphoblastic leukemia.
  • We report an 11-year-old child who, as supported by both clinical course and neuroimaging studies, developed an unusual complication eight years after completing therapy for acute lymphoblastic leukemia, gliomatosis cerebri.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasms, Neuroepithelial / pathology. Neoplasms, Second Primary / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy


43. Welker NC, Pavelec DM, Nix DA, Duchaine TF, Kennedy S, Bass BL: Dicer's helicase domain is required for accumulation of some, but not all, C. elegans endogenous siRNAs. RNA; 2010 May;16(5):893-903
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dicer's helicase domain is required for accumulation of some, but not all, C. elegans endogenous siRNAs.
  • We find that the helicase domain of Dicer is not necessary for microRNA (miRNA) processing, or RNA interference following exposure to exogenous double-stranded RNA.
  • Comparisons of wild-type and helicase-defective strains using deep-sequencing analyses show that the helicase domain is required by a subset of annotated endo-siRNAs, in particular, those associated with the slightly longer 26-nucleotide small RNA species containing a 5' guanosine.

  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2002 Nov 1;21(21):5875-85 [12411505.001]
  • [Cites] J Mol Biol. 2008 Jun 27;380(1):237-43 [18508075.001]
  • [Cites] Mol Cell. 2008 Jul 11;31(1):79-90 [18571451.001]
  • [Cites] Mol Cell. 2008 Jul 11;31(1):67-78 [18571452.001]
  • [Cites] Mol Cell. 2008 Aug 8;31(3):309-12 [18691963.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12897-902 [18723671.001]
  • [Cites] PLoS One. 2008;3(12):e4052 [19112503.001]
  • [Cites] BMC Bioinformatics. 2008;9:523 [19061503.001]
  • [Cites] Cell. 2009 Feb 20;136(4):642-55 [19239886.001]
  • [Cites] Mol Cell. 2009 Oct 23;36(2):231-44 [19800275.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18674-9 [19846761.001]
  • [Cites] Genetics. 2009 Dec;183(4):1283-95 [19797044.001]
  • [Cites] Annu Rev Biophys. 2008;37:317-36 [18573084.001]
  • [Cites] BMC Genomics. 2008;9:270 [18522735.001]
  • [Cites] Cell. 1999 Oct 15;99(2):123-32 [10535731.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):325-30 [11099033.001]
  • [Cites] Nature. 2001 Jan 18;409(6818):363-6 [11201747.001]
  • [Cites] Gene. 2001 Jan 24;263(1-2):103-12 [11223248.001]
  • [Cites] Cell. 2001 Jul 13;106(1):23-34 [11461699.001]
  • [Cites] Science. 2001 Sep 21;293(5538):2269-71 [11486053.001]
  • [Cites] Genes Dev. 2001 Oct 15;15(20):2654-9 [11641272.001]
  • [Cites] Curr Biol. 2002 Aug 6;12(15):1317-9 [12176360.001]
  • [Cites] Genome Biol. 2003;4(4):R28 [12702209.001]
  • [Cites] Curr Biol. 2003 May 13;13(10):807-18 [12747828.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):845-9 [14685240.001]
  • [Cites] Cell. 2004 Apr 2;117(1):69-81 [15066283.001]
  • [Cites] Cell. 2004 Jul 9;118(1):57-68 [15242644.001]
  • [Cites] Genetics. 1997 May;146(1):227-38 [9136012.001]
  • [Cites] J Virol. 1997 Dec;71(12):9400-9 [9371600.001]
  • [Cites] Science. 2006 Jan 13;311(5758):195-8 [16410517.001]
  • [Cites] Cell. 2006 Jan 27;124(2):343-54 [16439208.001]
  • [Cites] EMBO J. 2006 Feb 8;25(3):522-32 [16424907.001]
  • [Cites] RNA. 2006 Apr;12(4):589-97 [16489184.001]
  • [Cites] Nucleic Acids Res. 2006;34(12):3465-75 [16849434.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1193-207 [17174894.001]
  • [Cites] Science. 2007 Jan 12;315(5809):241-4 [17124291.001]
  • [Cites] Science. 2007 Jan 12;315(5809):244-7 [17158288.001]
  • [Cites] Curr Opin Struct Biol. 2007 Feb;17(1):138-45 [17194582.001]
  • [Cites] Nucleic Acids Res. 2007;35(8):e60 [17405769.001]
  • [Cites] Annu Rev Biochem. 2007;76:23-50 [17506634.001]
  • [Cites] Nat Struct Mol Biol. 2007 Jul;14(7):604-10 [17603500.001]
  • [Cites] Mol Cell. 2007 Aug 3;27(3):449-61 [17658285.001]
  • [Cites] J Biol Chem. 2007 Sep 28;282(39):28373-8 [17666393.001]
  • [Cites] EMBO J. 2007 Dec 12;26(24):5007-19 [18007599.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 May;9(5):391-401 [18414490.001]
  • [Cites] Nat Struct Mol Biol. 2008 Jun;15(6):581-90 [18500351.001]
  • [Cites] Nature. 2008 Jun 5;453(7196):798-802 [18463631.001]
  • [Cites] Nature. 2003 Jan 16;421(6920):231-7 [12529635.001]
  • (PMID = 20354150.001).
  • [ISSN] 1469-9001
  • [Journal-full-title] RNA (New York, N.Y.)
  • [ISO-abbreviation] RNA
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM067106-06; United States / NIGMS NIH HHS / GM / GM067106; United States / NIGMS NIH HHS / GM / R01 GM067106-06; United States / NCI NIH HHS / CA / CA04214; United States / NIGMS NIH HHS / GM / R01 GM076619; United States / NIGMS NIH HHS / GM / GM076619; United States / NIGMS NIH HHS / GM / R01 GM067106
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Helminth; 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 3.1.26.3 / Ribonuclease III; EC 3.6.4.13 / RNA Helicases
  • [Other-IDs] NLM/ PMC2856884
  •  go-up   go-down


44. Cockcroft A, Andersson N, Omer K, Ansari NM, Khan A, Chaudhry UU, Ansari U: One size does not fit all: local determinants of measles vaccination in four districts of Pakistan. BMC Int Health Hum Rights; 2009;9 Suppl 1:S4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] One size does not fit all: local determinants of measles vaccination in four districts of Pakistan.
  • Children were more likely to receive measles vaccination if the household was less vulnerable, if their mother had any formal education, if she knew at least one vaccine preventable disease, and if she had not heard of any bad effects of vaccination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19828062.001).
  • [ISSN] 1472-698X
  • [Journal-full-title] BMC international health and human rights
  • [ISO-abbreviation] BMC Int Health Hum Rights
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3226236
  •  go-up   go-down


45. Wallace LS, Ache KA: Hear all about it: nightly television news coverage of cervical cancer vaccination in the United States. J Low Genit Tract Dis; 2009 Jul;13(3):154-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each television news broadcast was categorized as follows: segment length (in seconds), network (American Broadcasting Company, Columbia Broadcasting Company, National Broadcasting Company, Cable News Network, or Fox Broadcasting Company), year of broadcast (2002-2007), and (4) presentation type.


46. Lin TL, Vala MS, Barber JP, Karp JE, Smith BD, Matsui W, Jones RJ: Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia; 2007 Sep;21(9):1915-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of acute lymphocytic leukemia differentiation by maintenance therapy.
  • Despite extensive study in many malignancies, maintenance therapy has clinically benefited only two diseases: acute lymphocytic leukemia (ALL) and acute promyelocytic leukemia (APL).
  • 6MP and MTX as used in ALL are also now usually added to maintenance ATRA for APL, based on data suggesting an improved disease-free survival.
  • The APL cell line NB4, the ALL cell lines REH and RS4;11, and patients' ALL blasts were incubated with ATRA, 6MP, and MTX in vitro.
  • All three drugs inhibited the clonogenic growth of the APL and ALL cell lines without inducing immediate apoptosis, but associated with induction of phenotypic differentiation.
  • The three drugs similarly upregulated lymphoid antigen expression, while decreasing CD34 expression, on patients' ALL blasts.
  • These data suggest that induction of leukemia progenitor differentiation plays an important role in the mechanism of action of maintenance therapy in ALL.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):774-80 [12610173.001]
  • [Cites] Br J Haematol. 2003 Apr;121(2):251-8 [12694246.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2375-6 [12802021.001]
  • [Cites] Nouv Rev Fr Hematol. 1984;26(6):371-8 [6597407.001]
  • [Cites] Cancer. 1987 Apr 1;59(7):1258-63 [3469011.001]
  • [Cites] Blood. 1987 Jun;69(6):1551-62 [3555647.001]
  • [Cites] J Clin Oncol. 1989 Dec;7(12):1816-23 [2585022.001]
  • [Cites] N Engl J Med. 1990 Jul 5;323(1):17-21 [2355954.001]
  • [Cites] Blood. 1991 Mar 1;77(5):1080-6 [1995093.001]
  • [Cites] Leukemia. 1991 May;5(5):425-31 [2033963.001]
  • [Cites] Br J Cancer. 1991 Jul;64(1):169-73 [1854617.001]
  • [Cites] Leukemia. 1992;6 Suppl 2:178-81 [1578927.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1744-9 [7934171.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Oct;271(1):193-9 [7965714.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1151-68 [7858247.001]
  • [Cites] Blood. 1995 May 15;85(10):2742-6 [7742535.001]
  • [Cites] Lancet. 1996 Jun 29;347(9018):1783-8 [8667921.001]
  • [Cites] J Immunol. 1996 Dec 1;157(11):4908-17 [8943395.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] J Immunol. 1997 Oct 1;159(7):3278-87 [9317126.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3569-77 [9808549.001]
  • [Cites] Leukemia. 1999 Feb;13(2):275-81 [10025902.001]
  • [Cites] Haematologica. 1999 Jan;84(1):36-58 [10091392.001]
  • [Cites] Exp Hematol. 2002 Nov;30(11):1273-82 [12423680.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3893-903 [12124315.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2225-33 [10090931.001]
  • [Cites] Blood. 1985 Jan;65(1):21-31 [3917311.001]
  • [Cites] Exp Cell Res. 1999 Apr 10;248(1):58-73 [10094813.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1192-200 [10438706.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1442-9 [15735032.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):853-62 [15755292.001]
  • [Cites] Nat Med. 2005 Jun;11(6):630-7 [15908956.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6361-9 [16778214.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • [Cites] Eur J Immunol. 2001 Apr;31(4):1261-7 [11298353.001]
  • [Cites] Immunol Res. 2000;22(2-3):281-98 [11339363.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3925-30 [11389036.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3496-506 [12032784.001]
  • [Cites] Blood. 2002 Jul 15;100(2):640-6 [12091359.001]
  • [Cites] Cell Growth Differ. 2002 Jun;13(6):275-83 [12114217.001]
  • [Cites] Pharmacol Ther. 2003 Dec;100(3):257-90 [14652113.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8955-61 [14695213.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2919-25 [15242869.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Feb;68(2):378-82 [5277089.001]
  • [Cites] Lancet. 1973 Jun 16;1(7816):1339-43 [4122739.001]
  • [Cites] Eur J Cancer. 1977 Apr-May;13(4-5):377-9 [194778.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 May;75(5):2458-62 [276884.001]
  • [Cites] Cancer Res. 1984 Jun;44(6):2421-9 [6586286.001]
  • [Cites] Blood. 1984 Oct;64(4):922-9 [6206904.001]
  • (PMID = 17611566.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA015396; United States / NCI NIH HHS / CA / P01 CA070970; United States / NCI NIH HHS / CA / K23 CA107040-04; United States / NCI NIH HHS / CA / K23 CA107040; United States / NCI NIH HHS / CA / P01 CA70970; United States / NCI NIH HHS / CA / P01 CA15396; United States / NCI NIH HHS / CA / CA107040-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Cytotoxins; 5688UTC01R / Tretinoin; E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS81581; NLM/ PMC2643128
  •  go-up   go-down


47. Ji Z, Mei FC, Miller AL, Thompson EB, Cheng X: Protein kinase A (PKA) isoform RIIbeta mediates the synergistic killing effect of cAMP and glucocorticoid in acute lymphoblastic leukemia cells. J Biol Chem; 2008 Aug 8;283(32):21920-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein kinase A (PKA) isoform RIIbeta mediates the synergistic killing effect of cAMP and glucocorticoid in acute lymphoblastic leukemia cells.
  • Protein kinase A (PKA) or cAMP-dependent protein kinase (cAPK) mediates the synergistic effects of cAMP- and glucocorticoid (GC)-induced apoptosis in lymphoid cells.
  • Using two human acute lymphoblastic leukemia cell (CEM) clones with respective GC-sensitive and GC-resistant phenotypes, we discovered that the PKA regulatory subunit isoform RII(beta) is preferentially expressed in the GC-sensitive clone C7-14 cells, whereas other intracellular cAMP receptors, including the exchange proteins directly activated by cAMP (Epac), are expressed at similar levels in both GC-sensitive and GC-resistant clones.
  • High RII(beta) expression level in C7-14 cells is associated with elevated total PKA cellular activity and cAMP sensitivity, which consequently lead to an increased basal PKA activity. cAMP analogs that selectively activate type II PKA recapitulate the effects of forskolin of promoting apoptosis and antagonizing AKT/PKB activity in both GC-sensitive and GC-resistant clones, whereas type I PKA-selective agonists do not.
  • These results demonstrate that PKA RII(beta) is responsible for increased GC sensitivity, critical for cAMP-mediated synergistic cell killing in CEM cells, and may represent a novel therapeutic target for GC-resistant lymphoid malignancy.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(15):5192-6 [3037538.001]
  • [Cites] J Biol Chem. 1986 Sep 15;261(26):12352-61 [2427518.001]
  • [Cites] Mol Endocrinol. 1990 Mar;4(3):465-75 [2342480.001]
  • [Cites] Annu Rev Biochem. 1990;59:971-1005 [2165385.001]
  • [Cites] Leuk Res. 1993 Jun;17(6):501-6 [8505847.001]
  • [Cites] Leuk Lymphoma. 1994 Nov;15(5-6):363-74 [7873993.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3861-8 [7579354.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Nov;21(1-3):33-61 [8822496.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2959-65 [9108416.001]
  • [Cites] J Neurosci. 1998 May 15;18(10):3639-49 [9570795.001]
  • [Cites] Blood. 1998 Jul 1;92(1):259-66 [9639525.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3684-93 [9721879.001]
  • [Cites] J Cell Physiol. 1999 Jul;180(1):71-80 [10362019.001]
  • [Cites] Mol Endocrinol. 2005 Jun;19(6):1569-83 [15817653.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):876-85 [16239906.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] J Biol Chem. 2007 Dec 28;282(52):37370-7 [17895245.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Histochem Cell Biol. 2000 Jul;114(1):1-7 [10959816.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):12864-70 [11278269.001]
  • [Cites] J Biol Chem. 2001 Feb 9;276(6):4102-8 [11110787.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11497-504 [11801596.001]
  • [Cites] Leukemia. 2003 Jan;17(1):17-25 [12529655.001]
  • [Cites] J Endocrinol. 2003 Jul;178(1):19-27 [12844332.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):20858-65 [14996839.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Sep;71(9):3580-3 [4372627.001]
  • [Cites] Cancer Res. 1977 Oct;37(10):3785-91 [269011.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3608-12 [6190178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jun;85(11):3703-7 [3375237.001]
  • (PMID = 18544528.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / 1 R90 DK071505-01; United States / NIDDK NIH HHS / DK / 1 T90 DK070109-01; United States / NCI NIH HHS / CA / CA041407; United States / NIGMS NIH HHS / GM / GM066170
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit; 0 / Glucocorticoids; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins c-bcl-2; E0399OZS9N / Cyclic AMP; EC 2.7.11.1 / Oncogene Protein v-akt
  • [Other-IDs] NLM/ PMC2494930
  •  go-up   go-down


48. Steingrímsson E: All for one, one for all: alternative promoters and Mitf. Pigment Cell Melanoma Res; 2008 Aug;21(4):412-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] All for one, one for all: alternative promoters and Mitf.
  • [MeSH-major] Gene Expression Regulation. Microphthalmia-Associated Transcription Factor / genetics. Promoter Regions, Genetic / physiology
  • [MeSH-minor] Animals. Mice. Mice, Transgenic. Organ Specificity / genetics. Pigment Epithelium of Eye / metabolism. Protein Isoforms / genetics. Protein Isoforms / metabolism. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18503500.001).
  • [ISSN] 1755-1471
  • [Journal-full-title] Pigment cell & melanoma research
  • [ISO-abbreviation] Pigment Cell Melanoma Res
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Microphthalmia-Associated Transcription Factor; 0 / Mitf protein, mouse; 0 / Protein Isoforms; 0 / RNA, Messenger
  •  go-up   go-down


49. Share with women. Cord blood banking--what's it all about? J Midwifery Womens Health; 2008 Mar-Apr;53(2):161-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Share with women. Cord blood banking--what's it all about?
  • [MeSH-major] Blood Banks. Blood Donors. Directed Tissue Donation. Fetal Blood
  • [MeSH-minor] Female. Humans. Pregnancy. United States

  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18330049.001).
  • [ISSN] 1542-2011
  • [Journal-full-title] Journal of midwifery & women's health
  • [ISO-abbreviation] J Midwifery Womens Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Xiong RX, Zhong GQ, Song HX, Zhang JC, Ling Y: [Collagen spatial distribution in rapid atrial pacing dogs with or without superior vena cava and aortic root fat pad]. Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Feb;38(2):171-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Collagen spatial distribution in rapid atrial pacing dogs with or without superior vena cava and aortic root fat pad].
  • OBJECTIVE: To observe the collagen spatial distribution, collagen volume fraction (CVF) and Cx40, Cx43mRNA expressions in rapid atrial pacing dogs post vagal denervation by removing fat pad located between the medial superior vena cava and aortic root (SVC-Ao fat pad).
  • METHODS: Twenty-four dogs were randomly divided into unpaced sham operation group (S group, n = 8), Keeping SVC-Ao fat pad group (K group, n = 8) and Removing SVC-Ao fat pad group (R group, SVC-Ao fat pad was removed by surgical excision before pacing, n = 8).
  • K and R groups were paced for six weeks.
  • Six weeks later, all dogs were sacrificed, left atrium (LA), right atrium (RA), left atrial appendage (LAA), right atrial appendage (RAA) and atrial septum (AS) were collected and stained with HE or Masson Trichrome or frozen in liquid nitrogen for quantifying the expression of Cx40, Cx43 mRNA by Real-time quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR).
  • RESULTS: Spatial distribution of collagen fibers as well as CVF between S and R group were similar (all P > 0.05).
  • CVF was significantly higher in K group compared to R group, especially at LAA and AS locations (all P < 0.05).
  • Cx40mRNA expression in K group was significantly decreased in LA, RA, and significantly increased in LAA, RAA and AS compared those in S group (all P < 0.05), significantly lower in LA and RA while significantly higher in LAA and RAA compared to R group (all P < 0.05).
  • Cx43mRNA expression in K group was significantly reduced in LA, RA, LAA and RAA while significantly increased in AS compared to S group (all P < 0.05), significantly higher in LA, RA, RAA and AS while significantly lower in LAA compared to R group.
  • CONCLUSION: Pacing induced collagen remodeling and modulation on Cx40mRNA and Cx43 mRNA expressions could be partially attenuated by removing SVC-Ao fat pad suggesting vagal denervation plays a key role in the initiation and preservation of atrial fibrillation.
  • [MeSH-major] Atrial Fibrillation / metabolism. Cardiac Pacing, Artificial. Collagen / metabolism. Heart Atria / metabolism
  • [MeSH-minor] Animals. Connexin 43 / metabolism. Connexins / metabolism. Dogs. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Atrial Fibrillation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398567.001).
  • [ISSN] 0253-3758
  • [Journal-full-title] Zhonghua xin xue guan bing za zhi
  • [ISO-abbreviation] Zhonghua Xin Xue Guan Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Connexin 43; 0 / Connexins; 0 / RNA, Messenger; 0 / connexin 40; 9007-34-5 / Collagen
  •  go-up   go-down


51. De Stefano V, Sorà F, Rossi E, Chiusolo P, Laurenti L, Fianchi L, Zini G, Pagano L, Sica S, Leone G: The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost; 2005 Sep;3(9):1985-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment.
  • BACKGROUND: Thromboembolism can occur during acute leukemia, especially acute lymphoid leukemia (ALL) treated with L-asparaginase.
  • Yet, most reports are anecdotical and scarce data are available on the risk of thrombosis in acute myeloid leukemia (AML).
  • OBJECTIVES: To evaluate the risk of thrombosis in patients with acute leukemia.
  • PATIENTS AND METHODS: Three-hundred and seventy-nine consecutive adult patients with newly diagnosed acute leukemia were recruited in an observational cohort study conducted from January 1994 to December 2003.
  • Diagnosis was ALL in 69 patients, acute promyelocytic leukemia (APL; FAB subtype M3) in 31, and non-M3 AML in 279.
  • At diagnosis, thrombosis was a presenting manifestation in 13 cases (3.4% of the whole cohort): 1.4% in ALL, 9.6% in APL, and 3.2% in non-M3 AML patients.
  • Follow-up was carried out on 343 patients without thrombosis at diagnosis and further 11 thrombotic events (3.2%) were recorded.
  • At 6 months from diagnosis, the cumulative incidence of thrombosis was 10.6% in ALL, 8.4% in APL, and 1.7% in non-M3 AML patients.
  • The patients who received L-asparaginase had a 4.9-fold increased risk of thrombosis in comparison with those who did not (95% CI 1.5-16.0).
  • CONCLUSIONS: In patients with acute leukemia, the risk of thrombosis is not negligible.
  • Thombosis can be a presenting symptom at diagnosis in a significant portion of cases with APL (9.6%) and non-M3 AML (3.2%); a similar rate of thrombosis can occur during the subsequent course of the disease.
  • The incidence of symptomatic thrombosis at diagnosis is relatively low in ALL patients (1.4%), but is significantly increased by further treatment up to 10.6%.
  • [MeSH-major] Leukemia / complications. Thrombosis / etiology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Asparaginase / adverse effects. Female. Follow-Up Studies. Genetic Predisposition to Disease. Humans. Incidence. Male. Middle Aged. Risk

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16102104.001).
  • [ISSN] 1538-7933
  • [Journal-full-title] Journal of thrombosis and haemostasis : JTH
  • [ISO-abbreviation] J. Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


52. Tschan MP, Reddy VA, Ress A, Arvidsson G, Fey MF, Torbett BE: PU.1 binding to the p53 family of tumor suppressors impairs their transcriptional activity. Oncogene; 2008 May 29;27(24):3489-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transcription factor PU.1 is essential for terminal myeloid differentiation, B- and T-cell development, erythropoiesis and hematopoietic stem cell maintenance.
  • PU.1 functions as oncogene in Friend virus-induced erythroleukemia and as tumor suppressor in acute myeloid leukemias.
  • Moreover, Friend virus-induced erythroleukemia requires maintenance of PU.1 expression and the disruption of p53 function greatly accelerates disease progression.
  • It has been hypothesized that p53-mediated expression of the p21(Cip1) cell cycle inhibitor during differentiation of pre-erythroleukemia cells promotes selection against p53 function.
  • We demonstrate that PU.1 reduces the transcriptional activity of the p53 tumor suppressor family and thus inhibits activation of genes important for cell cycle regulation and apoptosis.
  • Lastly, knocking down endogenous PU.1 in p53 wild-type REH B-cell precursor leukemia cells leads to increased expression of the p53 target p21(Cip1).
  • [MeSH-minor] Apoptosis. Blotting, Western. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Humans. Immunoprecipitation. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Protein Isoforms. RNA, Small Interfering / pharmacology. Transcriptional Activation. Tumor Cells, Cultured. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18193090.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI49165; United States / NIDDK NIH HHS / DK / DK49886
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / proto-oncogene protein Spi-1; 0 / tumor suppressor protein p73
  •  go-up   go-down


53. Hansel TT, Benezet O, Kafé H, Ponitz HH, Cheung D, Engelstätter R, Barnes PJ: A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. Clin Ther; 2006 Jun;28(6):906-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was double blind with respect to the ciclesonide dose and open label for budesonide, as placebofor budesonide was not available.
  • Unlike budesonide, ciclesonide was not associated with significant urinary cortisol suppression in these patients.

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma in Children.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860173.001).
  • [ISSN] 0149-2918
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Pregnenediones; 51333-22-3 / Budesonide; S59502J185 / ciclesonide; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


54. Zhang XM, Wang HY, Luo YY, Ji LN: HLA-DQ, DR allele polymorphism of type 1 diabetes in the Chinese population: a meta-analysis. Chin Med J (Engl); 2009 Apr 20;122(8):980-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-DQ, DR allele polymorphism of type 1 diabetes in the Chinese population: a meta-analysis.
  • BACKGROUND: Type 1 diabetes (T1D) is a multifactorial disease.
  • In genetic type level, DRB1*04, DRB1*0301, DRB1*0901 were the susceptible alleles (all P < 0.05) and their merger ORs were 2.19, 6.43, 1.31, 3.83, and 8.08.
  • CONCLUSIONS: In the Chinese population, some HLA-DQ, DR alleles are relevant to T1D which are not totally the same as non-Chinese populations.
  • [MeSH-major] Diabetes Mellitus, Type 1 / genetics. HLA-DQ Antigens / genetics. HLA-DR Antigens / genetics. Polymorphism, Genetic / genetics
  • [MeSH-minor] Alleles. Asian Continental Ancestry Group / genetics. Genetic Predisposition to Disease / genetics. Humans

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19493426.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HLA-DQ Antigens; 0 / HLA-DR Antigens
  •  go-up   go-down


55. Lord Darzi: The first year of high quality care for all. Health Serv J; 2009 Jun 25;119(6162):17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The first year of high quality care for all.
  • [MeSH-major] Health Care Reform. Quality of Health Care / standards. State Medicine
  • [MeSH-minor] Efficiency, Organizational. Goals. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19634230.001).
  • [ISSN] 0952-2271
  • [Journal-full-title] The Health service journal
  • [ISO-abbreviation] Health Serv J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


56. Allewaert SJ, De Man RF, Dewulf D, Vanhoucke JL: Incidentally found enlarged lymph node: not innocent at all. Eur Radiol; 2005 Aug;15(8):1771-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidentally found enlarged lymph node: not innocent at all.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Dendritic Cells. Lymph Nodes / pathology. Sarcoma / diagnosis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):589-97 [11293908.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):817-21 [12153170.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1048-58 [9737236.001]
  • (PMID = 15378338.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


57. Sankar J, Arun S, Sankar MJ, Seth R, Thavraj V, Kabra SK, Vasantha M: 'Primary cutaneous mucormycosis during induction chemotherapy in a child with acute lymphoblastic leukemia'. Indian J Pediatr; 2009 Nov;76(11):1161-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Primary cutaneous mucormycosis during induction chemotherapy in a child with acute lymphoblastic leukemia'.
  • We report a child with acute lymphoblastic leukemia who developed primary cutaneous mucormycosis at the site of lumbar puncture during induction chemotherapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Mucormycosis / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Skin Diseases / chemically induced

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 1992 Mar;14 Suppl 1:S126-9 [1562684.001]
  • [Cites] J Pediatr. 1980 May;96(5):824-8 [6928943.001]
  • [Cites] Acta Chir Belg. 2005 Sep-Oct;105(5):551-3 [16315848.001]
  • [Cites] Am J Perinatol. 1998 Jan;15(1):35-8 [9475685.001]
  • [Cites] Pediatr Infect Dis. 1982 Mar-Apr;1(2):110-4 [6960330.001]
  • [Cites] J Am Acad Dermatol. 1997 Feb;36(2 Pt 2):336-41 [9039214.001]
  • [Cites] J Chemother. 1990 Aug;2(4):211-7 [2230904.001]
  • [Cites] Haematologica. 2000 Oct;85(10):1068-71 [11025599.001]
  • [Cites] Am J Dis Child. 1986 May;140(5):459-61 [3962940.001]
  • (PMID = 20072858.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


58. Carney DA, Westerman DA, Tam CS, Milner A, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Ritchie D, Came N, Seymour JF: Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia; 2010 Dec;24(12):2056-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
  • Fludarabine combination chemotherapy achieves high response rates in chronic lymphocytic leukemia (CLL) and indolent lymphoma.
  • The aim of this study was to investigate the incidence and characteristics of treatment-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) after treatment with fludarabine in combination for lymphoproliferative disorders and identify risk factors for its development.
  • Median overall survival post-t-MDS/AML diagnosis was 11 months.
  • Patients developing t-MDS/AML included 11/54 with follicular lymphoma (FL) (crude rate 20.4%), 5/82 with CLL (6.1%) and 3/24 with Waldenstrom macroglobulinemia or marginal zone lymphoma (12.5%).
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Myelodysplastic Syndromes / chemically induced. Neoplasms, Second Primary / chemically induced. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged


59. Al-Najar A, Naumann CM, Kaufmann S, Steinbach-Jensch A, Hamann MF, Jünemann KP, van der Horst C: Should being aged over 70 years hinder penile prosthesis implantation? BJU Int; 2009 Sep;104(6):834-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, the motivation of the patient and not the age of the patient should be the main determinant factor in this surgical procedure.

  • MedlinePlus Health Information. consumer health - Erectile Dysfunction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2011 Apr;185(4):1328 [22098970.001]
  • (PMID = 19338558.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


60. Schrappe M: Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia. Radiat Prot Dosimetry; 2008;132(2):130-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia.
  • Systematic enrollment of children and adolescents with acute lymphoblastic leukaemia (ALL) into clinical trials has allowed the establishment of prognostic parameters derived from initial diagnostic findings.
  • More important, these trials have significantly contributed to the reduction of disease recurrence as much as to the reduction of acute and late side effects.
  • Some problems that are related to the specificity of the parameters used for risk assessment were not overcome: high tumour load by white blood cell count (WBC), age and (rare) cytogenetic subtypes (e.g. t9;22) may characterise a significant proportion of children and adolescents with high-risk ALL.
  • Most patients who will eventually relapse do not present with characteristic features at initial diagnosis.
  • Using clone-specific polymerase chain reaction-based detection of minimal residual disease (MRD) as done in trial AIEOP-BFM ALL 2000 allowed a close surveillance of specific treatment elements when applied in MRD positive patients.
  • This may facilitate innovative chemotherapy approaches and a more rational use of allogeneic haematopoetic stem cell transplantation.
  • [MeSH-major] Clinical Trials as Topic. Disease Outbreaks / statistics & numerical data. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Risk Assessment / methods
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Genetic Predisposition to Disease / epidemiology. Genetic Predisposition to Disease / genetics. Humans. Incidence. Infant. Infant, Newborn. Male. Risk Factors

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19017727.001).
  • [ISSN] 0144-8420
  • [Journal-full-title] Radiation protection dosimetry
  • [ISO-abbreviation] Radiat Prot Dosimetry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


61. Din S, Dahele A, Fennel J, Aitken S, Shand AG, Arnott ID, Satsangi J: Use of methotrexate in refractory Crohn's disease: the Edinburgh experience. Inflamm Bowel Dis; 2008 Jun;14(6):756-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of methotrexate in refractory Crohn's disease: the Edinburgh experience.
  • BACKGROUND: In the two benchmark controlled trials in Crohn's disease (CD) supporting its use, methotrexate (MTX) was used as the immunosuppressant of choice in immunomodulatory-naive patients.
  • Low-dose oral therapy does not maintain long-term remission and is not a suitable alternative.
  • [MeSH-major] Crohn Disease / drug therapy. Immunosuppressive Agents / therapeutic use. Methotrexate / therapeutic use

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18275071.001).
  • [ISSN] 1078-0998
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunosuppressive Agents; 9PHQ9Y1OLM / Prednisolone; B72HH48FLU / Infliximab; MRK240IY2L / Azathioprine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


62. Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA, Lipton J: Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant; 2005 Nov;36(9):825-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease.
  • In all, 30 patients with CLL proceeded to myeloablative allogeneic BMT using related (n=20, 67%) or unrelated (n=10) donors, at the Princess Margaret Hospital (Toronto) (n=20) or the Leukemia/BMT Program of BC (Vancouver) (n=10), from 1989 to 2001.
  • Median (range) interval from diagnosis to BMT was 4.8 (0.3-13) years, median number of prior therapies was three and median age 48 years.
  • Both acute (RR=0.008, P=0.01) and chronic (RR=0.006, P=0.02) Graft-versus-host disease (GVHD) were associated with markedly decreased risk of relapse.
  • There is evidence for a strong graft-versus-leukemia effect associated with acute and chronic GVHD, resulting in near complete protection from relapse.
  • [MeSH-major] Bone Marrow Transplantation. Graft vs Host Disease / mortality. Graft vs Leukemia Effect. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Tissue Donors
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Histocompatibility Testing / methods. Humans. Male. Middle Aged. Recurrence. Remission Induction / methods. Retrospective Studies. Transplantation Conditioning / methods. Transplantation, Homologous. Whole-Body Irradiation / methods


63. Haupt A, Thamer C, Heni M, Ketterer C, Machann J, Schick F, Machicao F, Stefan N, Claussen CD, Häring HU, Fritsche A, Staiger H: Gene variants of TCF7L2 influence weight loss and body composition during lifestyle intervention in a population at risk for type 2 diabetes. Diabetes; 2010 Mar;59(3):747-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene variants of TCF7L2 influence weight loss and body composition during lifestyle intervention in a population at risk for type 2 diabetes.
  • RESEARCH DESIGN AND METHODS: We genotyped 309 German subjects at increased risk for type 2 diabetes for single nucleotide polymorphisms (SNPs) rs7903146, rs12255372, rs11196205, and rs7895340 in TCF7L2 and performed oral glucose tolerance tests before and after a 9-month lifestyle intervention.
  • RESULTS: After adjustment for confounding variables, we observed a negative impact of the type 2 diabetes allele of SNP rs7903146 on change in BMI (P = 0.0034) and on changes in nonvisceral (P = 0.0032) and visceral fat (P = 0.0165) during lifestyle intervention.
  • An association of rs7903146 with lifestyle intervention-induced changes in insulin secretion, glucose concentrations, liver fat, or insulin sensitivity were not detected (all P > 0.2).
  • [MeSH-major] Body Composition / genetics. Diabetes Mellitus, Type 2 / epidemiology. Diabetes Mellitus, Type 2 / genetics. Genetic Variation. TCF Transcription Factors / genetics. Weight Loss / genetics


64. Belczak CE, de Godoy JM, Ramos RN, de Oliveira MA, Belczak SQ, Caffaro RA: Is the wearing of elastic stockings for half a day as effective as wearing them for the entire day? Br J Dermatol; 2010 Jan;162(1):42-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Objective The aim of this work was to evaluate whether or not the use of compression stockings during part of the day would help in the reduction of evening oedema in patients with clinical, epidemiological, anatomical and physiopathological (CEAP) classifications C0 and C1.
  • Participants used three-quarter-length elastic compression stockings (20-30 mmHg) on three consecutive days for the entire day or only for the morning or they did not use the stockings at all.
  • Results Significant increases in volume were observed for both legs when stockings were not used compared with the use of stockings in the morning only.
  • However, use for half the day was better than not using the stockings at all.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19785617.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Vohnout B, Vachulová A, Blazícek P, Dukát A, Fodor G, Lietava J: Evaluation of alternative calculation methods for determining LDL cholesterol. Vnitr Lek; 2008 Oct;54(10):961-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Ninety three subjects free of coronary heart disease were considered.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vnitr Lek. 2008 Oct;54(10):943-4 [19009757.001]
  • (PMID = 19009762.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Cholesterol, LDL; 0 / Reagent Kits, Diagnostic; 0 / Triglycerides
  •  go-up   go-down


66. Depuydt P, Benoit D, Vogelaers D, Decruyenaere J, Vandijck D, Claeys G, Verschraegen G, Blot S: Systematic surveillance cultures as a tool to predict involvement of multidrug antibiotic resistant bacteria in ventilator-associated pneumonia. Intensive Care Med; 2008 Apr;34(4):675-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Aged. Anti-Bacterial Agents / pharmacology. Anti-Bacterial Agents / therapeutic use. Bacteriological Techniques. Belgium / epidemiology. Cells, Cultured. Early Diagnosis. Female. Humans. Male. Middle Aged. Prevalence. Prospective Studies. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hosp Infect. 2006 Sep;64(1):7-15 [16822583.001]
  • [Cites] Chest. 2002 Jul;122(1):262-8 [12114368.001]
  • [Cites] Chest. 1999 Feb;115(2):462-74 [10027448.001]
  • [Cites] Chest. 1998 Feb;113(2):412-20 [9498961.001]
  • [Cites] Intensive Care Med. 2006 Nov;32(11):1773-81 [16983549.001]
  • [Cites] Crit Care Med. 2003 Jul;31(7):1964-70 [12847390.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Jan 1;165(1):41-6 [11779728.001]
  • [Cites] Eur Respir J. 2002 Aug;20(2):432-9 [12212978.001]
  • [Cites] Crit Care Med. 2006 Mar;34(3):903-5 [16505677.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416 [15699079.001]
  • [Cites] Ann Intern Med. 2001 Feb 20;134(4):298-314 [11182841.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Sep;49(9):3663-7 [16127037.001]
  • [Cites] Chest. 1997 Mar;111(3):676-85 [9118708.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Nov;162(5):1731-7 [11069804.001]
  • [Cites] Eur Respir J. 2003 Dec;22(6):876-82 [14680072.001]
  • [Cites] Chest. 2005 Oct;128(4):2706-13 [16236946.001]
  • [Cites] Chest. 2005 Feb;127(2):589-97 [15706001.001]
  • [Cites] Am Rev Respir Dis. 1991 May;143(5 Pt 1):1121-9 [2024824.001]
  • [Cites] Arch Intern Med. 1999 May 24;159(10):1127-32 [10335691.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Aug;160(2):608-13 [10430736.001]
  • [Cites] Clin Infect Dis. 2000 Sep;31 Suppl 4:S131-8 [11017862.001]
  • [Cites] Arch Intern Med. 2002 Jan 28;162(2):185-90 [11802752.001]
  • [Cites] Semin Respir Crit Care Med. 2006 Feb;27(1):23-8 [16508878.001]
  • [Cites] Chest. 1993 Oct;104(4):1230-5 [8404198.001]
  • [Cites] Crit Care Med. 2006 Mar;34(3):653-9 [16505649.001]
  • [Cites] Chest. 1993 Oct;104(4):993-5 [8404237.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2691-3 [17182995.001]
  • [Cites] Crit Care Med. 2005 Jul;33(7):1538-48 [16003060.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jan;48(1):224-8 [14693543.001]
  • [Cites] Crit Care Med. 2004 Nov;32(11):2183-90 [15640629.001]
  • [Cites] Chest. 2002 Dec;122(6):2183-96 [12475862.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Feb;157(2):531-9 [9476869.001]
  • (PMID = 18066522.001).
  • [ISSN] 0342-4642
  • [Journal-full-title] Intensive care medicine
  • [ISO-abbreviation] Intensive Care Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


67. Zhao JL, Sun BG, Wen QZ, Zhang JJ, Jin W, Xue JX, Zhuang WY: [Effect of early and non-early controlled-release of arsenic-trioxide eluting stents on restenosis inhibition in a canine model]. Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Jun;35(6):571-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Bare stents, stents coated with polybutyl methacrylate/Nano silica (containing 200 microg of As(2)O(3) per stent or not), stents coated with polybutyl methacrylate/Nano silica inside (containing 200 microg of As(2)O(3) per stent or not) and poly-lactide-co-glycolide (PLGA) outside were deployed with mild oversizing in left anterior descending (LAD) and circumflex coronary arteries (LCX)of 30 canines (n = 6, 12 stents for each group).
  • [MeSH-minor] Angioplasty, Balloon, Coronary / adverse effects. Angioplasty, Balloon, Coronary / methods. Animals. Disease Models, Animal. Dogs

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17711724.001).
  • [ISSN] 0253-3758
  • [Journal-full-title] Zhonghua xin xue guan bing za zhi
  • [ISO-abbreviation] Zhonghua Xin Xue Guan Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


68. Farrow SJ, Kingsley GH, Scott DL: Interventions for foot disease in rheumatoid arthritis: a systematic review. Arthritis Rheum; 2005 Aug 15;53(4):593-602
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventions for foot disease in rheumatoid arthritis: a systematic review.
  • This finding was supported by a CCT and prospective observational studies.
  • Prospective observational studies suggest that forefoot arthroplasty and first metatarsophalangeal joint implants, but not plantar callous debridement, are effective.


69. French D, Wilkinson MR, Yang W, de Chaisemartin L, Cook EH, Das S, Ratain MJ, Evans WE, Downing JR, Pui CH, Relling MV: Global gene expression as a function of germline genetic variation. Hum Mol Genet; 2005 Jun 15;14(12):1621-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We determined the germline status of 16 well-characterized functional polymorphisms in 126 children with newly diagnosed acute lymphoblastic leukemia (ALL).
  • Gene expression values were adjusted for ALL-subtype-specific patterns.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / physiology. Genetic Variation. Germ-Line Mutation. Glucuronosyltransferase / genetics. Glutathione Transferase / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827851211 for PMID:15857854 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15857854.001).
  • [ISSN] 0964-6906
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / CA 51001; United States / NCI NIH HHS / CA / CA 78224; United States / NIGMS NIH HHS / GM / U01 GM61374; United States / NIGMS NIH HHS / GM / U01 GM61393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.4.1.- / UGT1A1 enzyme; EC 2.4.1.17 / Glucuronosyltransferase; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


70. Roman-Gomez J, Agirre X, Jiménez-Velasco A, Arqueros V, Vilas-Zornoza A, Rodriguez-Otero P, Martin-Subero I, Garate L, Cordeu L, San José-Eneriz E, Martin V, Castillejo JA, Bandrés E, Calasanz MJ, Siebert R, Heiniger A, Torres A, Prosper F: Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol; 2009 Mar 10;27(8):1316-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic regulation of microRNAs in acute lymphoblastic leukemia.
  • PURPOSE: To identify microRNAs (miRNAs) epigenetically regulated in acute lymphoblastic leukemia (ALL).
  • METHODS: We first examined ALL-derived cell lines for the presence of abnormal levels of two different histone modifications (trimethylation of H3 lysine 4 [K4H3me3] and dimethylation of H3 lysine 9 [K9H3me2]) in the 5'UTR regions around CpG islands of 78 miRNAs by chromatin immunoprecipitation (ChIP)-on-ChIP analysis.
  • Methylation status (methylation-specific polymerase chain reaction [PCR]) and expression (quantitative PCR) of miRNAs showing a pattern of histone modifications linked to a closed chromatin structure were analyzed in a panel of six ALL cell lines and in 353 ALL patients.
  • Complete consistency in the correlation between both histone marks, the presence of DNA methylation around these miRNAs, and their expression patterns was confirmed in the six ALL cell lines.
  • Estimated disease-free survival (DFS) and overall survival (OS) at 14 years were 78% and 71% for nonmethylated patients and 24% and 28% for methylated patients (P = .00001 for both).
  • [MeSH-major] Epigenesis, Genetic. MicroRNAs / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. CpG Islands. DNA Methylation. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19164206.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


71. Avci Z, Alioglu B, Anuk D, Ozbek OY, Azap OK, Ozbek N: Double invasive fungal infection and typhlitis in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol; 2008 Mar;25(2):99-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double invasive fungal infection and typhlitis in children with acute lymphoblastic leukemia.
  • Here the authors report on two adolescent patients with acute lymphoblastic leukemia who developed combined invasive pulmonary aspergillosis and hepatosplenic candidiasis during chemotherapy.
  • [MeSH-major] Aspergillosis / etiology. Candidiasis / etiology. Liver Diseases / etiology. Lung Diseases, Fungal / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Splenic Diseases / etiology. Typhlitis / etiology


72. Sadananda Adiga MN, Chandy S, Ramaswamy G, Appaji L, Krishnamoorthy L: Homocysteine, vitamin B12 and folate status in pediatric acute lymphoblastic leukemia. Indian J Pediatr; 2008 Mar;75(3):235-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homocysteine, vitamin B12 and folate status in pediatric acute lymphoblastic leukemia.
  • OBJECTIVE: The cause of majority of acute leukemias is unknown, but likely to involve interaction of environment, hematopoitic development and weak susceptibility loci within an individual's genetic constitution.
  • The present study evaluates the association between plasma levels of homocysteine, folate and vitamin B12 and acute lymphoblastic leukemia.
  • METHODS: Plasma levels of homocysteine, folate and vitamin B12 were compared between cases of acute lymphoblastic leukemia and age and sex matched normal controls.
  • Although individually vitamin B12 and homocysteine were not significant different between cases and controls, the combined effect of all three parameters was significantly different (P< 0.001), with 83.3% of correct classification of cases and controls was obtained by discriminate function analysis.
  • CONCLUSION: The data provide evidence for the role of folate, vitamin B12 and homocysteine levels in acute lymphoblastic leukemia, suggesting that gene-environment interaction may be an important factor in the development of acute lymphoblastic leukemia.
  • [MeSH-major] Folic Acid / blood. Homocysteine / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Vitamin B 12 / blood

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2001 Dec 8;358(9297):1935-40 [11747917.001]
  • [Cites] Thromb Haemost. 1998 Dec;80(6):874-7 [9869152.001]
  • [Cites] Clin Chem. 1998 Feb;44(2):311-6 [9474030.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1089-96 [11588136.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jul;9(7):657-63 [10919734.001]
  • [Cites] Food Chem Toxicol. 2002 Aug;40(8):1113-7 [12067572.001]
  • [Cites] Thromb Res. 2003 May 1;110(2-3):87-91 [12893022.001]
  • [Cites] Eur J Pediatr. 1998 Apr;157 Suppl 2:S54-9 [9587027.001]
  • [Cites] Clin Chem. 1982 Oct;28(10):2161-5 [7127748.001]
  • [Cites] J Nutr. 2002 Aug;132(8 Suppl):2382S-2387S [12163697.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jun;8(6):513-8 [10385141.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12810-5 [10536004.001]
  • (PMID = 18376090.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0LVT1QZ0BA / Homocysteine; 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


73. Father Thomas Nairn: Ethics of right relation: all are responsible for all. Health Prog; 2010 Nov-Dec;91(6):64-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethics of right relation: all are responsible for all.
  • [MeSH-major] Religion and Medicine. Right to Die. Social Justice
  • [MeSH-minor] Catholicism. Health Care Reform. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21140851.001).
  • [ISSN] 0882-1577
  • [Journal-full-title] Health progress (Saint Louis, Mo.)
  • [ISO-abbreviation] Health Prog
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Ramirez-Ruiz E, Lee W: Gamma-ray bursts: Maybe not so old after all. Nature; 2009 Aug 27;460(7259):1091-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma-ray bursts: Maybe not so old after all.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Nature. 2009 Oct 1;461(7264):605
  • (PMID = 19713925.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] England
  •  go-up   go-down


75. Roberts A: "All politics is local": the importance of grassroots advocacy. Bull Am Coll Surg; 2006 Oct;91(10):16-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "All politics is local": the importance of grassroots advocacy.
  • [MeSH-major] Legislation, Medical. Lobbying
  • [MeSH-minor] General Surgery / legislation & jurisprudence. Societies, Medical / legislation & jurisprudence. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18551976.001).
  • [ISSN] 0002-8045
  • [Journal-full-title] Bulletin of the American College of Surgeons
  • [ISO-abbreviation] Bull Am Coll Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Hou SM: Taiwan-China health partnership is urgently needed for all. Lancet; 2007 Apr 21;369(9570):1345-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Taiwan-China health partnership is urgently needed for all.
  • [MeSH-major] Global Health. International Cooperation. Politics. Travel
  • [MeSH-minor] Animals. Birds. China. Humans. Taiwan

  • MedlinePlus Health Information. consumer health - International Health.
  • MedlinePlus Health Information. consumer health - Traveler's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lancet. 2007 Feb 24;369(9562):623-5 [17321295.001]
  • [CommentOn] Lancet. 2007 Feb 24;369(9562):616 [17321291.001]
  • (PMID = 17448816.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


77. Kato Y, Takano Y, Kobayashi M, Ito F, Hara T, Yanagisawa T, Hoshi Y, Eto Y: Retinochoroidal infarction during the treatment of acute lymphoblastic leukemia. Pediatr Int; 2006 Oct;48(5):495-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinochoroidal infarction during the treatment of acute lymphoblastic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Choroid / blood supply. Infarction / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Retinal Vessels

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16970790.001).
  • [ISSN] 1328-8067
  • [Journal-full-title] Pediatrics international : official journal of the Japan Pediatric Society
  • [ISO-abbreviation] Pediatr Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


78. Crazzolara R, Bernhard D: CXCR4 chemokine receptors, histone deacetylase inhibitors and acute lymphoblastic leukemia. Leuk Lymphoma; 2005 Nov;46(11):1545-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCR4 chemokine receptors, histone deacetylase inhibitors and acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is a malignancy with the potential to infiltrate the liver, spleen, lymph nodes and brain.
  • Because overexpression of CXCR4 on ALL cells is associated with high extramedullary organ infiltration and shorter disease-free survival, numerous pharmacological agents affecting CXCR4 have currently been investigated.
  • Wider recognition of the role of CXCR4 in ALL and manipulation of this important mechanism may lead to novel approaches in the treatment and outcome of this disease.
  • [MeSH-major] Histone Deacetylase Inhibitors. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Receptors, CXCR4 / physiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236608.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Receptors, CXCR4
  • [Number-of-references] 41
  •  go-up   go-down


79. Liu J, Yu F, Dai P, Han DY, Yang SM, Wang GJ, Hong MD, Kang DY, Zhang X: [Mutation of Gap junction protein beta 2 gene and treatment outcome of cochlear implantation in cochlear implantation recipients]. Zhonghua Yi Xue Za Zhi; 2009 Feb 24;89(7):433-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mutation of Gap junction protein beta 2 gene and treatment outcome of cochlear implantation in cochlear implantation recipients].
  • OBJECTIVE: To investigate the Gap junction protein beta 2 (GJB2) gene mutation in cochlear implantation (CI) recipients and the treatment outcome of CI in the CI recipients with GJB2 gene mutation.
  • METHODS: Peripheral blood samples were collected from 253 CI recipients with autosomal recessive non-syndromic hearing impairment (NSHI), 174 males and 79 females, aged (8 +/- 9) (112 months-52.7 years), and 301 children with normal hearing level as controls.
  • PCR was used to detect the GJB2 mutations.
  • The auditory threshold with CI and speech recognition of the CI recipients with GJB2 mutation were compared with those of the CI recipients without GJB2 mutation (control group).
  • Questionnaire survey, with meaningful auditory integration scale (MAIS), categories of auditory performance (CAP), and speech intelligibility rating (SIR), was used for young infants.
  • RESULTS: Sixty-seven of the 253 CI recipients (26.5%) were found to have GJB2 mutations.
  • One novel mutation, GJB2 235delC/598G > A, was identified.
  • The detection rates of GJB2 mutations in the CI recipients were significantly higher than those among the controls (all P < 0.05).
  • The postoperative outcomes of CI in both the GJB2 gene mutation positive and negative groups were very good, however, without significant differences among these 2 groups (all P > 0.05).
  • CONCLUSION: GJB2 gene mutation is one of the major causes for CI recipients with autosomal recessive NSHI.
  • The treatment outcomes of CI recipients with GJB2 gene mutations under 7 years old are satisfying.
  • [MeSH-major] Cochlear Implantation. Connexins / genetics. Deafness / genetics. Mutation
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Hearing Disorders and Deafness.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19567088.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Connexins; 127120-53-0 / connexin 26
  •  go-up   go-down


80. Wang L, Cai SR, Zhang CH, He YL, Zhan WH, Wu H, Peng JJ: [Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on angiogenesis of gastric cancer in a nude mouse model]. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Nov;11(6):565-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Nude mouse model with human gastric cancer was established by subcutaneously inoculating human gastric cancer cell line SGC-7901.
  • The expressions of MMP-7 between ARB groups and control group were not significantly different.
  • [MeSH-major] Angiotensin II Type 1 Receptor Blockers / pharmacology. Angiotensin-Converting Enzyme Inhibitors / pharmacology. Stomach Neoplasms / blood supply. Stomach Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Neovascularization, Pathologic

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031137.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Angiotensin-Converting Enzyme Inhibitors
  •  go-up   go-down


81. Liang Y, Yang ZX, Zhu Y, Wang Y, Zeng XM, Deng AM, Zhong RQ: [Study on association of BAFF receptors gene expression and primary biliary cirrhosis]. Zhonghua Yi Xue Za Zhi; 2007 Jan 9;87(2):128-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To explore the relationship between expression level of B cell-activating factor belonging to the TNF family (BAFF) receptor (BAFF-R) gene family and primary biliary cirrhosis (PBC).
  • B cell maturation antigen (BCMA), transmembrane activator and CAMI-interactor (TACI) and BAFF-R mRNA of peripheral blood mononuclear cells (PBMCs) in 30 healthy people and 30 PBC patients were measured.
  • The correlation between TACI and IgM was significant (P < 0.05), but not for GGT or ALP (both P > 0.05).
  • [MeSH-major] B-Cell Activation Factor Receptor / genetics. Gene Expression. Liver Cirrhosis, Biliary / genetics
  • [MeSH-minor] Adult. Alkaline Phosphatase / blood. B-Cell Maturation Antigen / genetics. Female. Humans. Immunoglobulin M / blood. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transmembrane Activator and CAML Interactor Protein / genetics. gamma-Glutamyltransferase / blood

  • Genetic Alliance. consumer health - Primary biliary cirrhosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418023.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / B-Cell Activation Factor Receptor; 0 / B-Cell Maturation Antigen; 0 / Immunoglobulin M; 0 / RNA, Messenger; 0 / Transmembrane Activator and CAML Interactor Protein; EC 2.3.2.2 / gamma-Glutamyltransferase; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


82. Hunt JW, Anderson BS, Phillips BM, Tjeerdema RS, Richard N, Connor V, Worcester K, Angelo M, Bern A, Fulfrost B, Mulvaney D: Spatial relationships between water quality and pesticide application rates in agricultural watersheds. Environ Monit Assess; 2006 Oct;121(1-3):245-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In-stream nitrate concentrations were not significantly correlated with either the amount of pesticides applied, in-stream pesticide concentrations, or in-stream toxicity (all p > 0.30).

  • MedlinePlus Health Information. consumer health - Pesticides.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Toxicol Chem. 2004 Nov;23(11):2649-54 [15559280.001]
  • [Cites] J Environ Qual. 2004 Mar-Apr;33(2):419-48 [15074794.001]
  • [Cites] Environ Toxicol Chem. 2005 Apr;24(4):954-65 [15839571.001]
  • [Cites] Environ Pollut. 2003;124(3):523-32 [12758031.001]
  • [Cites] Water Res. 2004 Jul;38(13):3092-102 [15261548.001]
  • [Cites] J Environ Qual. 2005 Apr 20;34(3):836-41 [15843646.001]
  • [Cites] Environ Monit Assess. 2003 Oct-Nov;88(1-3):283-310 [14570419.001]
  • [Cites] Environ Toxicol Chem. 2005 Apr;24(4):966-72 [15839572.001]
  • [Cites] Environ Pollut. 2006 Jun;141(3):402-8 [16225973.001]
  • [Cites] J Agric Food Chem. 2000 Sep;48(9):4071-8 [10995316.001]
  • [Cites] Arch Environ Contam Toxicol. 2000 Jul;39(1):20-31 [10790498.001]
  • [Cites] Environ Toxicol Chem. 2003 Oct;22(10):2375-84 [14552002.001]
  • [Cites] Water Sci Technol. 2004;49(3):125-34 [15053107.001]
  • [Cites] Environ Monit Assess. 2003 Feb;82(1):83-112 [12602624.001]
  • (PMID = 16758283.001).
  • [ISSN] 0167-6369
  • [Journal-full-title] Environmental monitoring and assessment
  • [ISO-abbreviation] Environ Monit Assess
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Nitrates; 0 / Pesticides
  •  go-up   go-down


83. Yip HK, Chang LT, Sun CK, Chen MC, Yang CH, Hung WC, Hsieh YK, Fang CY, Hang CL, Wu CJ, Chang HW: Platelet activity is a biomarker of cardiac necrosis and predictive of untoward clinical outcomes in patients with acute myocardial infarction undergoing primary coronary stenting. Circ J; 2006 Jan;70(1):31-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet activity is a biomarker of cardiac necrosis and predictive of untoward clinical outcomes in patients with acute myocardial infarction undergoing primary coronary stenting.
  • BACKGROUND: The relationship between platelet activity and myocardial injury in patients with ST-segment elevated (ST-se) acute myocardial infarction (AMI) remains unclear.

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16377921.001).
  • [ISSN] 1346-9843
  • [Journal-full-title] Circulation journal : official journal of the Japanese Circulation Society
  • [ISO-abbreviation] Circ. J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / P-Selectin
  •  go-up   go-down


84. Rubnitz JE, Wichlan D, Devidas M, Shuster J, Linda SB, Kurtzberg J, Bell B, Hunger SP, Chauvenet A, Pui CH, Camitta B, Pullen J, Children's Oncology Group: Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol; 2008 May 01;26(13):2186-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.
  • PURPOSE: To prospectively determine the prognostic significance of the TEL-AML1 fusion in children with acute lymphoblastic leukemia (ALL).
  • PATIENTS AND METHODS: TEL gene status was determined for 926 patients with B-precursor ALL enrolled on the Pediatric Oncology Group ALinC 16 trials and patients were observed for a median time of 8 years.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Expression Regulation, Leukemic. Gene Rearrangement. Oncogene Proteins, Fusion / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Prognosis. Proportional Hazards Models. Prospective Studies. Risk Assessment. Sex Factors. Survival Rate. Time Factors. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18445843.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / CA 30969; United States / NCI NIH HHS / CA / CA 98543; United States / NCI NIH HHS / CA / P30 CA-21765; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R21 CA-73983; United States / NCI NIH HHS / CA / U10 CA029139; United States / NCI NIH HHS / CA / U10 CA098543
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  • [Other-IDs] NLM/ NIHMS698549; NLM/ PMC4485397
  •  go-up   go-down


85. Osorio R, Osorio E, Aguilera FS, Tay FR, Pinto A, Toledano M: Influence of application parameters on bond strength of an "all in one" water-based self-etching primer/adhesive after 6 and 12 months of water aging. Odontology; 2010 Jul;98(2):117-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of application parameters on bond strength of an "all in one" water-based self-etching primer/adhesive after 6 and 12 months of water aging.
  • Our aim was to evaluate the influence of different application parameters on microtensile bond strength (microTBS) of an "all in one" water-based self-etching primer/adhesive to dentin.
  • Extracted human third molars had their crowns transversally sectioned next to the dentinoenamel junction.
  • Prompt-L-Pop adhesive was applied using five modes:.
  • (1) following the manufacturer's instructions (MI);.
  • (2) after 36% H(3)PO(4) etching (15 s) (AG);.
  • (3) after H(3)PO(4) etching and 5% NaOCl (2 min) with constant agitation (HG);.
  • (4) as a double layer (DL); and (5) for double the application time (DT).
  • Resin build-ups were constructed with Tetric Ceram.
  • After storage for 24 h, 6 months, or 12 months in water at 37 degrees C, the specimens were vertically sectioned into beams (cross-sectional areas, 1 mm(2)).
  • Each beam was tested in an Instron Machine at 0.5 mm/min.
  • Analysis of variance and Student-Newman-Keuls were used (P < 0.05).
  • Bonded interfaces were examined by scanning electron microscopy (SEM) and transmission electron microscopy (TEM).
  • The highest microTBS values were obtained when AG was used, and the lowest when MI was employed.
  • The HG, DL, and DT modes resulted in similar microTBS values.
  • Water storage reduced microTBS in all groups except the MI group.
  • SEM and TEM revealed hybrid layer and resin tag formation in all groups.
  • Applied after AG, HG, DL, and DT, Prompt L-Pop adhesive provided adequate bond strength to dentin after 24 h of water storage.
  • Bond strength decreased when specimens were stored in distilled water for 6 or 12 months.
  • [MeSH-major] Dental Bonding. Dentin / ultrastructure. Dentin-Bonding Agents / chemistry. Resin Cements / chemistry
  • [MeSH-minor] Acid Etching, Dental. Adhesiveness. Composite Resins / chemistry. Curing Lights, Dental. Dental Stress Analysis / instrumentation. Humans. Humidity. Materials Testing. Microscopy, Electron, Scanning. Microscopy, Electron, Transmission. Phosphoric Acids / chemistry. Sodium Hypochlorite / chemistry. Stress, Mechanical. Surface Properties. Temperature. Tensile Strength. Time Factors. Water / chemistry

  • Hazardous Substances Data Bank. PHOSPHORIC ACID .
  • Hazardous Substances Data Bank. SODIUM HYPOCHLORITE .
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Oral Sci. 2004 Aug;112(4):376-83 [15279658.001]
  • [Cites] J Mater Sci Mater Med. 2007 Dec;18(12):2355-61 [17569004.001]
  • [Cites] Am J Dent. 2001 Feb;14(1):22-4 [11806474.001]
  • [Cites] Dent Mater. 2008 Jan;24(1):90-101 [17442386.001]
  • [Cites] Dent Mater. 2005 Feb;21(2):110-24 [15681009.001]
  • [Cites] J Dent Res. 2005 Apr;84(4):350-4 [15790742.001]
  • [Cites] Dent Mater. 2007 Dec;23(12):1542-8 [17379296.001]
  • [Cites] J Biomed Mater Res A. 2006 Apr;77(1):128-35 [16392135.001]
  • [Cites] J Biomed Mater Res. 1998 Dec 5;42(3):465-72 [9788511.001]
  • [Cites] J Dent Res. 2002 Jul;81(7):472-6 [12161459.001]
  • [Cites] J Adhes Dent. 2001 Summer;3(2):153-67 [11570684.001]
  • [Cites] J Dent. 1997 Sep;25(5):355-72 [9241954.001]
  • [Cites] Dent Mater. 1998 Jan;14(1):44-50 [9972150.001]
  • [Cites] Am J Dent. 1998 Aug;11(4):154-9 [10388368.001]
  • [Cites] Am J Dent. 2002 Aug;15(4):252-5 [12572644.001]
  • [Cites] Dent Mater. 2001 Sep;17(5):373-80 [11445203.001]
  • [Cites] J Dent Res. 1996 Sep;75(9):1706-15 [8952625.001]
  • [Cites] J Dent Res. 1999 Feb;78(2):699-705 [10029469.001]
  • [Cites] Am J Dent. 1996 Dec;9(6):240-4 [9545876.001]
  • [Cites] Eur J Oral Sci. 1999 Oct;107(5):400-13 [10515206.001]
  • [Cites] Dent Mater. 2000 Sep;16(5):311-23 [10915892.001]
  • [Cites] Eur J Oral Sci. 1995 Dec;103(6):368-74 [8747672.001]
  • [Cites] Am J Dent. 1997 Apr;10(2):66-70 [9545892.001]
  • [Cites] Dent Mater. 2000 Jul;16(4):255-65 [10831780.001]
  • [Cites] J Dent Res. 1992 Aug;71(8):1530-40 [1506519.001]
  • [Cites] Am J Dent. 1999 Oct;12(5):250-5 [10649917.001]
  • [Cites] Oper Dent. 2002 May-Jun;27(3):289-96 [12022462.001]
  • [Cites] J Dent. 2008 Dec;36(12):1068-73 [18922612.001]
  • [Cites] Dent Mater. 1998 Nov;14(6):394-8 [10483400.001]
  • [Cites] Dent Mater. 2007 Jul;23(7):885-92 [16949659.001]
  • [Cites] J Adhes Dent. 2008 Feb;10(2):135-44 [18512511.001]
  • [Cites] Dent Mater. 2001 Jul;17(4):296-308 [11356206.001]
  • [Cites] Int J Prosthodont. 1994 Jul-Aug;7(4):302-6 [7993540.001]
  • [Cites] J Dent Res. 1999 Apr;78(4):906-11 [10326735.001]
  • [Cites] Dent Mater. 1998 Mar;14(2):99-105 [10023198.001]
  • [Cites] Dent Mater. 1991 Apr;7(2):74-83 [1936644.001]
  • [Cites] Dent Mater. 2001 Mar;17(2):122-6 [11163381.001]
  • [Cites] Am J Dent. 2002 Oct;15(5):305-8 [12537339.001]
  • [Cites] J Dent. 2001 Jan;29(1):55-61 [11137639.001]
  • [Cites] Am J Dent. 1997 Oct;10(5):219-23 [9522695.001]
  • [Cites] Oper Dent. 1999 Mar-Apr;24(2):81-8 [10483444.001]
  • [Cites] Am J Dent. 2000 Nov;13(Spec No):25D-30D [11763914.001]
  • [Cites] Am J Dent. 1996 Aug;9(4):140-4 [9002787.001]
  • [Cites] Dent Mater. 1996 Jul;12 (4):236-44 [9002841.001]
  • [Cites] J Biomed Mater Res. 2002;63(3):306-11 [12115762.001]
  • [Cites] J Adhes Dent. 2008 Jun;10(3):183-8 [18652266.001]
  • [Cites] J Dent Res. 2005 Feb;84(2):118-32 [15668328.001]
  • [Cites] Am J Dent. 1998 Jun;11(3):118-22 [9823072.001]
  • [Cites] J Dent. 1997 Nov;25(6):441-58 [9604576.001]
  • [Cites] Oper Dent. 2001 Jan-Feb;26(1):97-104 [11203783.001]
  • [Cites] Dent Mater. 2003 Jul;19(5):399-405 [12742435.001]
  • [Cites] J Dent. 2006 Jan;34(1):77-85 [15979226.001]
  • [Cites] J Biomed Mater Res. 1999 Nov;47(2):198-203 [10449630.001]
  • [Cites] Oper Dent. 2002 May-Jun;27(3):218-22 [12025819.001]
  • [Cites] Biomaterials. 2005 Mar;26(9):1035-42 [15369692.001]
  • (PMID = 20652789.001).
  • [ISSN] 1618-1255
  • [Journal-full-title] Odontology
  • [ISO-abbreviation] Odontology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Composite Resins; 0 / Dentin-Bonding Agents; 0 / Phosphoric Acids; 0 / Prompt L-Pop; 0 / Resin Cements; 0 / Tetric ceram; 059QF0KO0R / Water; DY38VHM5OD / Sodium Hypochlorite; E4GA8884NN / phosphoric acid
  •  go-up   go-down


86. Ojalvo Holgado MJ, Sanz del Forcallo J, Casado Naranjo I: [Carcinomatous polyradiculopathy induced by acute lymphoblastic leukemia]. Neurologia; 2007 May;22(4):249-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinomatous polyradiculopathy induced by acute lymphoblastic leukemia].
  • [Transliterated title] Meningopolirradiculopatía carcinomatosa por leucemia linfoblástica aguda.
  • [MeSH-major] Polyradiculopathy. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Spinal Cord Neoplasms

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17492518.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


87. Rudant J, Orsi L, Menegaux F, Petit A, Baruchel A, Bertrand Y, Lambilliotte A, Robert A, Michel G, Margueritte G, Tandonnet J, Mechinaud F, Bordigoni P, Hémon D, Clavel J: Childhood acute leukemia, early common infections, and allergy: The ESCALE Study. Am J Epidemiol; 2010 Nov 1;172(9):1015-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood acute leukemia, early common infections, and allergy: The ESCALE Study.
  • This study investigated the role of factors considered related to early stimulation of the immune system in the etiology of childhood acute leukemia.
  • Included were 634 acute lymphoblastic leukemia cases, 86 acute myeloblastic leukemia cases, and 1,494 controls aged ≥1 year.
  • Negative associations were observed between acute lymphoblastic leukemia and birth order (P for trend < 0.0001), attendance at a day-care center before age 1 year (odds ratio (OR) = 0.8, 95% confidence interval (CI): 0.6, 1.1), prolonged breastfeeding (OR = 0.7, 95% CI: 0.5, 1.0), repeated early common infections (OR = 0.7, 95% CI: 0.6, 0.9), regular contact with farm animals (OR = 0.6, 95% CI: 0.5, 0.8), frequent farm visits in early life (OR = 0.4, 95% CI: 0.3, 0.6), and history of asthma (OR = 0.7, 95% CI: 0.4, 1.0) or eczema (OR = 0.7, 95% CI: 0.6, 0.9).
  • Results support the hypothesis that repeated early infections and asthma may play a role against childhood acute leukemia.
  • [MeSH-major] Hypersensitivity / epidemiology. Infection / epidemiology. Leukemia, Myeloid, Acute / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Allergy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20807738.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


88. Engel ME, Hiebert SW: Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia. Cancer Treat Res; 2010;145:127-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
  • The existence of non-random mutations in critical regulators of cell growth and differentiation is a recurring theme in cancer pathogenesis and provides the basis for our modern, molecular approach to the study and treatment of malignant diseases.
  • Nowhere is this more true than in the study of leukemogenesis, where research has converged upon a critical group of genes involved in hematopoietic stem and progenitor cell self-renewal and fate specification.
  • Together they contribute to approximately one-third of acute myelogenous leukemia (AML) and one-quarter of acute lymphoblastic leukemia (ALL) cases, making RUNX1 and CBFbeta the most frequently affected genes known in the pathogenesis of acute leukemia.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Core Binding Factor beta Subunit / genetics. Gene Expression Regulation, Leukemic / genetics. Leukemia, Myeloid, Acute / genetics. Mutation. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / physiology
  • [MeSH-minor] Cell Transformation, Neoplastic / genetics. Hematopoiesis. Humans. Transcription, Genetic. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306249.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA064140
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Core Binding Factor beta Subunit; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / RUNX1 protein, human
  • [Number-of-references] 120
  •  go-up   go-down


89. Li T, Zhou J, Deng Z, Fu C, Jiang H, Gao Z, Wang J, Ren H, Wang P: [Expression of FGF-2 and osteopontin in non-small cell lung cancer]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Nov;34(11):1114-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of FGF-2 and osteopontin in non-small cell lung cancer].
  • OBJECTIVE: To investigate the expression of fibroblast growth factor-2 (FGF-2) and osteopontin (OPN) in non-small cell lung cancer (NSCLC) tissues and analyze the correlation between FGF-2 and OPN.
  • The effect of FGF-2 on OPN expression at mRNA and protein level in A549 cell was examined by RT-PCR and Western blot.
  • The expression of FGF-2 and OPN was closely related to TNM stages and the lymph node metastasis (all Ps<0.01), but not to histological types, sex, and age of NSCLC patients (all Ps>0.05).A positive correlation was found between the expression of FGF-2 and OPN in NSCLC (r=0.552,P<0.01).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Fibroblast Growth Factor 2 / metabolism. Lung Neoplasms / metabolism. Osteopontin / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952401.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / SPP1 protein, human; 103107-01-3 / Fibroblast Growth Factor 2; 106441-73-0 / Osteopontin
  •  go-up   go-down


90. Treviño LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, Pui CH, Evans WE, Relling MV: Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol; 2009 Dec 10;27(35):5972-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our aim was to identify the genetic basis of interindividual variability in methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia (ALL).

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827857024 for PMID:19901119 [PharmGKB] .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 Aug 2;357(5):443-53 [17634449.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):977-83 [17603485.001]
  • [Cites] Clin Pharmacol Ther. 2007 Dec;82(6):726-33 [17473846.001]
  • [Cites] Pharmacogenomics. 2007 Jul;8(7):787-802 [18240907.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4365-6 [18802144.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] Lancet. 2000 Nov 11;356(9242):1667-71 [11089838.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1689-99 [11375950.001]
  • [Cites] J Biol Chem. 2001 Sep 21;276(38):35669-75 [11477075.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3832-4 [12411325.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):538-49 [12571262.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):553-6 [12571264.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3084-91 [12915598.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2167-79 [15152062.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] Pharmacogenetics. 2004 Jul;14(7):429-40 [15226675.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Aug;54(2):146-52 [15148625.001]
  • [Cites] Pharmacogenomics. 2004 Oct;5(7):819-34 [15469405.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] J Pharm Sci. 1981 Nov;70(11):1194-8 [7299661.001]
  • [Cites] N Engl J Med. 1983 Nov 3;309(18):1094-104 [6353235.001]
  • [Cites] Lancet. 1984 Feb 18;1(8373):359-62 [6141424.001]
  • [Cites] J Clin Oncol. 1983 Mar;1(3):208-16 [6607976.001]
  • [Cites] N Engl J Med. 1986 Feb 20;314(8):471-7 [3456079.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1539-44 [2778483.001]
  • [Cites] Ann Intern Med. 1989 Oct 15;111(8):641-9 [2802419.001]
  • [Cites] Blood. 1991 Nov 15;78(10):2514-9 [1824248.001]
  • [Cites] Gut. 1993 Aug;34(8):1081-5 [8174958.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1667-72 [8040679.001]
  • [Cites] Pharmacotherapy. 1995 Mar-Apr;15(2):144-9 [7624260.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] Clin Pharmacol Ther. 1999 Jan;65(1):29-39 [9951428.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):17159-63 [10358072.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4194-201 [15308564.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] Drug Metab Dispos. 2005 Mar;33(3):434-9 [15608127.001]
  • [Cites] Pharmacogenet Genomics. 2005 Jul;15(7):513-22 [15970799.001]
  • [Cites] Blood. 2005 Jul 15;106(2):717-20 [15797993.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):117-29 [16491071.001]
  • [Cites] Am J Hum Genet. 2006 Apr;78(4):629-44 [16532393.001]
  • [Cites] N Engl J Med. 2006 Mar 23;354(12):1264-72 [16554528.001]
  • [Cites] Curr Opin Hematol. 2006 Jul;13(4):260-5 [16755223.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Jul;318(1):395-402 [16627748.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Aug;318(2):521-9 [16702441.001]
  • [Cites] Nat Genet. 2006 Aug;38(8):904-9 [16862161.001]
  • [Cites] Pharmacogenet Genomics. 2006 Dec;16(12):873-9 [17108811.001]
  • [Cites] Ann Intern Med. 2006 Nov 21;145(10):749-57 [17116919.001]
  • [Cites] Curr Opin Pediatr. 2007 Feb;19(1):15-22 [17224657.001]
  • [Cites] Clin Pharmacol Ther. 2007 Mar;81(3):362-70 [17215845.001]
  • [Cites] Nat Genet. 2007 May;39(5):645-9 [17401363.001]
  • [Cites] Blood. 2007 May 15;109(10):4151-7 [17264302.001]
  • [Cites] Science. 2007 Jun 8;316(5830):1488-91 [17478681.001]
  • [Cites] Arthritis Rheum. 2007 Jun;56(6):1765-75 [17530705.001]
  • [Cites] Pharmacogenet Genomics. 2007 Aug;17(8):647-56 [17622941.001]
  • [Cites] Mol Endocrinol. 2007 Aug;21(8):1769-80 [17519356.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):591-4 [17632545.001]
  • (PMID = 19901119.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / U01 HL65899; United States / NCI NIH HHS / CA / CA 078224; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / CA 51001; United States / NHLBI NIH HHS / HL / U01 HL065899; United States / NCI NIH HHS / CA / R01 CA078224; United States / NIGMS NIH HHS / GM / U01GM61374; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NCI NIH HHS / CA / P30 CA021765; United States / NIGMS NIH HHS / GM / U01 GM061374; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Organic Anion Transporters; 0 / SLCO1B1 protein, human; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2793040
  •  go-up   go-down


91. Yuan JH, Li YQ, Yang XY: Inhibition of epigallocatechin gallate on orthotopic colon cancer by upregulating the Nrf2-UGT1A signal pathway in nude mice. Pharmacology; 2007;80(4):269-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of epigallocatechin gallate on orthotopic colon cancer by upregulating the Nrf2-UGT1A signal pathway in nude mice.
  • Epigallocatechin gallate (EGCG), a key active ingredient in green tea, has many anti-carcinogenic activities.
  • The aim of the present study was to investigate whether EGCG could prevent the occurrence or metastases of orthotopic colon cancer and probe the underlined mechanisms.
  • We observed the inhibition of EGCG on growth and metastases of colon tumor implanted orthotopically in the cecum of nude mice.
  • Immunohistochemistry and Western-blotting analysis were used to detect NF-E2-related factor 2 (Nrf2) protein expressions.
  • RT-PCR was also applied to detect the mRNA levels of Nrf2, uridine 5'-diphosphate-glucuronosyltransferase (UGT) 1A, UGT1A8 and UGT1A10 in colon tumors.
  • As a result, the inhibition rates on tumor growth in the 3 EGCG groups were significantly different (all p < 0.001) compared with the control group.
  • In addition, different doses of EGCG were able to inhibit liver and pulmonary metastases to varying degrees.
  • The protein level of Nrf2 and the mRNA levels of Nrf2, UGT1A, UGT1A8 and UGT1A10 significantly increased in EGCG-treated mice in comparison with the control group (all p < 0.01).
  • The results demonstrated that EGCG has a preventive effect on the growth and liver and pulmonary metastases of orthotopic colon cancer in nude mice, and this anticancer effect could be partly caused by activating the Nrf2-UGT1A signal pathway.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Catechin / analogs & derivatives. Colonic Neoplasms / drug therapy. Glucuronosyltransferase / physiology. NF-E2-Related Factor 2 / physiology. Signal Transduction / drug effects
  • [MeSH-minor] Animals. HT29 Cells. Humans. Lung Neoplasms / secondary. Male. Mice. Mice, Inbred BALB C. Mice, Nude. RNA, Messenger / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17657175.001).
  • [ISSN] 1423-0313
  • [Journal-full-title] Pharmacology
  • [ISO-abbreviation] Pharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / NF-E2-Related Factor 2; 0 / RNA, Messenger; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate; EC 2.4.1.17 / Glucuronosyltransferase
  •  go-up   go-down


92. Armstrong EM, Carpenter DP, Hojnacki M: Whose deaths matter? Mortality, advocacy, and attention to disease in the mass media. J Health Polit Policy Law; 2006 Aug;31(4):729-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whose deaths matter? Mortality, advocacy, and attention to disease in the mass media.
  • Our analysis of the cross-disease and cross-temporal variation in media attention suggests that who suffers from a disease as well as how many suffer are critical factors in explaining why some diseases get more attention than others.
  • We also find a positive link between the size of organizational communities that take an interest in disease and media attention, though this finding depends on the characteristics of those communities.
  • Finally, this study also reveals the limitations of relying on single-disease case studies-and particularly HIV/AIDS-to understand how and why disease captures public attention.
  • Many previous inferences about media attention that have been drawn from the case of AIDS are not reflective of the attention allocated to other diseases.
  • [MeSH-major] Attention. Disease. Mass Media. Mortality / trends. Patient Advocacy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16971544.001).
  • [ISSN] 0361-6878
  • [Journal-full-title] Journal of health politics, policy and law
  • [ISO-abbreviation] J Health Polit Policy Law
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


93. Hijiya N, Liu W, Sandlund JT, Jeha S, Razzouk BI, Ribeiro RC, Rubnitz JE, Howard SC, Kyzer EP, Redd DS, Cheng C, Rivera GK, Hudson MM, Relling MV, Pui CH: Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: lack of therapeutic role of local irradiation. Leukemia; 2005 Aug;19(8):1399-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: lack of therapeutic role of local irradiation.
  • To assess the prognosis of overt testicular disease at diagnosis of acute lymphoblastic leukemia, and any therapeutic role of irradiation for this involvement, we reviewed the data of 811 boys treated on St Jude studies Total X--XI (early period) and Total XII-XIV (recent period).
  • In all, 19 boys (2.3%) had testicular disease at diagnosis.
  • In the early period, patients with testicular leukemia had a poorer overall survival (OS) (P=0.003), event-free survival (EFS) (P=0.064), and higher cumulative incidence of relapse (P=0.041) than did other patients.
  • During the recent period, patients with and without overt testicular leukemia did not differ in OS (P=0.257), EFS (P=0.102), or cumulative incidence of relapse (P=0.51).
  • In a multivariate analysis, OS was lower for patients with testicular disease than for those without the involvement in the early period (P=0.047) but not in the recent one (P=0.75).
  • Both patients who received irradiation for residual testicular disease at the end of induction subsequently died of leukemia.
  • Of the other 17 patients who did not receive irradiation, only one developed testicular relapse in combination with bone marrow relapse.
  • In conclusion, the prognostic impact of overt testicular disease has diminished.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Testicular Neoplasms / radiotherapy


94. Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D: FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood; 2005 Jan 15;105(2):812-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.
  • FMS-like tyrosine kinase 3 (FLT3) is almost universally expressed in B-precursor childhood acute lymphoblastic leukemia (ALL).
  • We determined the antileukemic activity of CEP-701, a potent and selective FLT3 inhibitor, in 8 ALL cell lines and 39 bone marrow samples obtained at diagnosis from infants and children with various subtypes of ALL.
  • We conclude that the FLT3 inhibitor CEP-701 effectively suppresses FLT3-driven leukemic cell survival.
  • [MeSH-major] Carbazoles / pharmacology. Gene Expression Regulation, Leukemic. Indoles / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Proto-Oncogene Proteins / antagonists & inhibitors. Proto-Oncogene Proteins / genetics. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Receptor Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Age Factors. Apoptosis / drug effects. Child. DNA-Binding Proteins / genetics. Enzyme Inhibitors / pharmacology. Gene Rearrangement. Genotype. Histone-Lysine N-Methyltransferase. Humans. Infant. Myeloid-Lymphoid Leukemia Protein. Phenotype. Ploidies. Proto-Oncogenes / genetics. Transcription Factors / genetics. Tumor Cells, Cultured. fms-Like Tyrosine Kinase 3

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15374878.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA095600; United States / NCI NIH HHS / CA / CA60441; United States / NCI NIH HHS / CA / CA70970; United States / NCI NIH HHS / CA / CA90668; United States / NCI NIH HHS / CA / CA91177
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbazoles; 0 / DNA-Binding Proteins; 0 / Enzyme Inhibitors; 0 / Indoles; 0 / MLL protein, human; 0 / Proto-Oncogene Proteins; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; DO989GC5D1 / lestaurtinib; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


95. Chiou CC, Seibel NL, Derito FA, Bulas D, Walsh TJ, Groll AH: Concomitant Candida epiglottitis and disseminated Varicella zoster virus infection associated with acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2006 Nov;28(11):757-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant Candida epiglottitis and disseminated Varicella zoster virus infection associated with acute lymphoblastic leukemia.
  • Acute epiglottitis by nonbacterial pathogens is an uncommon but life-threatening clinical entity.
  • Herein, we report the concomitant occurrence of Candida epiglottitis and mucosal and visceral Varicella zoster virus infection in a child with acute lymphoblastic leukemia.
  • Both infections were atypical in their presentation, occurred in a severely immunocompromised host, and required invasive procedures for diagnosis.
  • [MeSH-major] Candidiasis / complications. Candidiasis / microbiology. Epiglottitis / microbiology. Herpes Zoster / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications


96. Pichler H, Möricke A, Mann G, Teigler-Schlegel A, Niggli F, Nebral K, König M, Inthal A, Krehan D, Dworzak MN, Janousek D, Harbott J, Schrappe M, Gadner H, Strehl S, Haas OA, Panzer-Grümayer R, Attarbaschi A, Berlin-Frankfurt-Münster (BFM) Study Group: Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy. Br J Haematol; 2010 Apr;149(1):93-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy.
  • The presence of a dicentric chromosome dic(9;20) has been reported to have an unfavourable prognosis in children with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL).
  • As outcome may be influenced by type and composition of treatment, we analyzed 19 BCP-ALL patients with dic(9;20) who have been treated with ALL-BFM (Berlin-Frankfurt-Münster) protocols that included a 4-drug induction and subsequent consolidation therapy.
  • Eight patients had no molecular disease after induction and another eight patients had levels < or =10(-4) after consolidation therapy.
  • Of note, there was a tendency for extramedullary disease in case of relapse (two of three relapses with central nervous system involvement).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Aberrations. Chromosomes, Human, Pair 20 / genetics. Chromosomes, Human, Pair 9 / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067563.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


97. Kumar P, Agrawal A, Shah AK, Gambhir RP, Galagali A, Chaudhry R: Gastrointestinal stromal tumours: Our experience. Indian J Surg; 2010 Apr;72(2):112-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The advent of effective chemotherapy for GIST has altered but not diminished the role of surgery which remains the standard therapy for all resectable non-metastatic tumours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1992 Jan;215(1):68-77 [1731651.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):706-14 [8317611.001]
  • [Cites] Am J Surg Pathol. 1993 Sep;17(9):887-97 [8394653.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):407-16 [9130987.001]
  • [Cites] Am J Surg. 1997 May;173(5):390-4 [9168073.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):278-81 [9891765.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Surgery. 2000 Oct;128(4):604-12 [11015094.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1134-42 [11048809.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):383-9 [11296107.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):578-82 [11431711.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Hum Pathol. 2002 May;33(5):466-77 [12094371.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S52-9 [12528773.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):171-6 [12949790.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):669-76 [12152168.001]
  • [Cites] J Clin Pathol. 2001 Feb;54(2):96-102 [11215292.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):183-5 [11863213.001]
  • [Cites] Chir Ital. 2002 Mar-Apr;54(2):127-31 [12038102.001]
  • (PMID = 23133220.001).
  • [ISSN] 0972-2068
  • [Journal-full-title] The Indian journal of surgery
  • [ISO-abbreviation] Indian J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3452505
  • [Keywords] NOTNLM ; CD117 / GIST / Imatinib / Mesylate
  •  go-up   go-down


98. Louis ED, Ferreira JJ: How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord; 2010 Apr 15;25(5):534-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Essential tremor (ET) is among the more prevalent neurological disorders, yet prevalence estimates have varied enormously, making it difficult to establish prevalence with precision. We:.
  • (1) reviewed the worldwide prevalence of ET in population-based epidemiological studies, (2) derived as precisely as possible an estimate of disease prevalence, and (3) examined trends and important differences across studies.
  • This possible gender preference is interesting given clinical, epidemiological, and pathological associations between ET and Parkinson's disease.
  • Precise prevalence estimates such as those we provide are important because they form the numerical basis for planned public health initiatives, provide data on the background occurrence of disease for family studies, and offer clues about the existence of environmental or underlying biological factors of possible mechanistic importance.

  • Genetic Alliance. consumer health - Tremor.
  • Genetic Alliance. consumer health - Essential tremor.
  • MedlinePlus Health Information. consumer health - International Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Movement Disorder Society.
  • (PMID = 20175185.001).
  • [ISSN] 1531-8257
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 53
  •  go-up   go-down


99. Patel JV, Caslake MJ, Vyas A, Cruickshank JK, Prabhakaran D, Bhatnagar D, Reddy KS, Lip GY, Mackness MI, Hughes EA, Durrington PN: Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations. Atherosclerosis; 2010 Apr;209(2):579-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations.
  • INTRODUCTION: Coronary heart disease (CHD) is exceptionally prevalent amongst globally dispersed migrant groups originating from the Indian subcontinent, but the contribution of dyslipidaemia to their increased risk remains poorly defined.
  • [MeSH-major] Coronary Disease / epidemiology. Lipoproteins, LDL / blood. Triglycerides / blood

  • Genetic Alliance. consumer health - Heart Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2009. Published by Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19922937.001).
  • [ISSN] 1879-1484
  • [Journal-full-title] Atherosclerosis
  • [ISO-abbreviation] Atherosclerosis
  • [Language] eng
  • [Grant] United Kingdom / British Heart Foundation / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Apolipoproteins B; 0 / Cholesterol, HDL; 0 / Lipoproteins, LDL; 0 / Triglycerides; 0 / oxidized low density lipoprotein
  •  go-up   go-down


100. Kang S, Yang YJ, Wu YL, Chen YT, Li L, Tian Y: Myocardium and microvessel endothelium apoptosis at day 7 following reperfused acute myocardial infarction. Microvasc Res; 2010 Jan;79(1):70-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myocardium and microvessel endothelium apoptosis at day 7 following reperfused acute myocardial infarction.
  • OBJECTIVES: This study was to investigate the salvaged myocardial and microvascular endothelial cells apoptosis at the first week of reperfused acute myocardial infarction (AMI).
  • The acute myocardial infarction and reperfusion model was created, and pathologic myocardial tissue was collected at day 7 following left anterior descending coronary artery reperfusion, and detected by transmission electron microscope, in situ cell apoptosis detection (TUNEL method), Real-time Quantitative Polymerase Chain Reaction and Western blot.
  • CONCLUSIONS: The overexpressions of Fas and Bax or the low expression of Bcl-2 in the infarcted and marginal heart tissue may play an important role in the acceleration of myocardial and endothelial apoptosis at 7th day following reperfused acute myocardial infarction.

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19913038.001).
  • [ISSN] 1095-9319
  • [Journal-full-title] Microvascular research
  • [ISO-abbreviation] Microvasc. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / bcl-2-Associated X Protein
  •  go-up   go-down






Advertisement